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There were circa 285 million adults with diabetes in the world in 2010 and 
approximately 90-95% of them had type 2 diabetes mellitus (Shaw et al. 2010, 
International Diabetes Federation 2011). The prevalence of diabetes patients increased 
from 194 million in 2003, and it is expected to be approximately 439 million by 2030. 
In Finland, the number of subjects with diabetes is more than 250 000 and also in here 
90% of the patients have type 2 diabetes mellitus (Diabetesliitto 2011). Also in Finland 
the number of patients with diabetes is expected to raise, even double during next 10-15 
years. Type 2 diabetes mellitus is very under-diagnosed and even half of the patients 
have not been diagnosed (Harris 1993). Type 2 diabetes mellitus is associated with 
severe and disabling comorbidities, such as nephropathy and retinopathy. The treatment 
of the comorbidities is expensive and often leads to hospitalizations. Early diagnosis 
would help diminishing the amount of diabetic complications (Colagiuri et al 2002). In 
1997 diabetes took about 12% of the costs of the health care system in Finland (Kangas 
2002). Approximately 90% of this amount was taken by the treatment of diabetic 
complications, which can partly be prevented.  
 
Patients with diabetes typically use a wide variety of drugs concurrently. In addition to 
antidiabetic medicine, patients with type 2 diabetes mellitus also have for example 
antihyperlipidemic, antihypertensive and antiplatelet medications. Polypharmacy 
significantly increases the risk of interactions (Reimche et al. 2011). Potential 
interactions can occur between different antidiabetic drugs, and between antidiabetic 
drugs and other widely co-administered pharmacological agents. Drug interactions 
cause major costs through unnecessary medications and increased number of 
hospitalizations (McDonnell and Jacobs 2002). A significant interaction has been 
reported between the antihyperglycemic agents sulphonylureas and the antihypertensive 
agents angiotensin-converting enzyme (ACE) inhibitors (Arauz-Pacheco et al. 1990; 
Herings et al. 1995; Moore et al. 1997; Morris et al. 1997; Thamer et al. 1999). 
Together these compounds decrease blood glucose concentration more than 
sulphonylureas alone and might cause hypoglycemic episodes in patients with type 2 
diabetes mellitus. The mechanism of the interaction is not known.  
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El-Batran and co-workers (2004) reported that fosinopril (ACE inhibitor) and gliclazide 
(sulphonylurea) administered together cause a greater hypoglycemic effect in control 
rats and in a rat model of diabetes than gliclazide alone. On the basis of the study, 
gliclazide and fosinopril were chosen for test items for the current study. The main 
purpose of the study was to clarify the mechanism of the interaction between 
sulphonylureas and ACE inhibitors. Since a pathological condition, for example type 2 
diabetes mellitus, might have an effect on the pharmacokinetics of drugs, the purpose 
was also to compare the interaction in control rats and in an animal model of type 2 
diabetes mellitus. No known single animal species is exactly identical to human 
diabetes in all its complexity. However, different models can be used as tools for 
studying the onset, the mechanisms and the treatment of type 2 diabetes mellitus. Goto-
Kakizaki (GK) rat model was chosen for this study because it is widely known, well 
characterized and versatile. 
 
This work consists of two parts: the literature review and the experimental study. The 
aim of the literature review was to consider type 2 diabetes mellitus as a disease and to 
acquaint with the medication. Another purpose was to clarify different mechanisms of 
interactions and to describe some of the typical interactions. In addition to these, the 
aim was to concentrate on the characteristics of various rat disease models and their use 
in research. The aim of the experimental study was to investigate the hypoglycemic 
interaction of fosinopril and gliclazide in control rats and in rat model of diabetes by 
examining the effects of fosinopril on the pharmacokinetics of gliclazide. Also the 
effects of experimental diabetes on pharmacokinetics of gliclazide after single and 
repeated dosing were studied. To study the pharmacokinetics of the test items, 
approximately 700 plasma samples were collected after single and repeated p.o. and/or 
i.v. administration. A high performance liquid chromatography tandem mass 
spectrometry (HPLC-MS/MS) method was developed for the measurement of the test 
item concentrations in the plasma samples and the pharmacokinetic parameters were 
determined. Blood glucose concentrations were determined regularly during the study 
to explore the effects of the test items on blood glucose. Oral glucose tolerance (OGT) 




I REVIEW OF THE LITERATURE 
 
 
2 TYPE 2 DIABETES MELLITUS 
 
Diabetes mellitus is a group of diseases characterized by chronic hyperglycemia and 
other metabolic abnormalities resulting from the deficient action of insulin. Diabetes 
has several disabling complications and if untreated, it will lead to death. Subjects with 
diabetes have a lower life expectancy (Gu et al. 1998). The cause of diabetes is partly 
unknown. Inheritance is a very important factor as well as external factors, such as diet 
and former diseases. There are almost 300 million adults in the world with diabetes and 
90-95% of them have type 2 diabetes mellitus (Shaw et al. 2010, International Diabetes 
Federation 2011). 
 
2.1 The role of insulin 
 
Insulin is a hormone secreted by the -cells in the islets of Langerhans (Cheatham and 
Kahn 1995). The most important factor stimulating endogenous insulin release is the 
elevation of plasma glucose concentration in the circulation. After meals carbohydrates 
absorb from the bowel to the circulation and the blood glucose level rises. As a result, 
the insulin secretion from the -cells in the pancreas increases. Glucose enters the 
pancreatic -cells using glucose transporter 2 (GLUT2) (Navarro-Tableros et al. 2007). 
This leads to a reduction of efflux of the adenosine triphosphate (ATP) -dependent K
+
-
channel and depolarization. The depolarization causes the opening of the voltage-gated 
Ca
2+
-channels and influx of Ca
2+
-ions. Insulin granules are then released from vesicles 
into the blood stream by exocytosis. Insulin rapidly lowers blood glucose concentration 
and this in return diminishes the release of insulin and insulin levels return to basal 
values (Cheatham and Kahn 1995). Normal pancreas produces small amounts of insulin 
constantly to control the function of liver and the basal metabolism.  
 
There are insulin receptors all over the body, but the most essential tissues for insulin 
action are the liver, the muscular tissue and the adipose tissue (Cheatham and Kahn 
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1995). Insulin affects the metabolism of glucose, lipids and proteins. In the muscular 
and the adipose tissue, insulin enhances the intake of glucose into the tissues. In the 
muscular tissue, it also enhances the storing of glucose into glycogen. In the liver, 
insulin enhances the storing of glucose by inhibiting gluconeogenesis and 
glycogenolysis and by enhancing the production of glycogen. Insulin also affects the 
metabolism of lipids. Insulin reduces the lipolysis and the concentration of free fatty 
acids and enhances the storing of triglycerides. In the liver, insulin stimulates the 
formation of fatty acids and triglycerides. In the adipose tissue, insulin enhances the 
intake of fatty acids and the synthesis of triglycerides. In addition to this, insulin 
enhances the protein synthesis and the intake of amino acids. Insulin also reduces the 
catabolism of proteins. 
 
2.2 Characters of type 2 diabetes mellitus 
 
Type 2 diabetes mellitus is characterized by insulin resistance and disordered insulin 
secretion from the pancreas (WHO 1999). Type 2 diabetes mellitus develops as a result 
of -cell dysfunction, peripheral insulin resistance and elevated hepatic glucose 
production. However, it is not known which is the primary abnormality and which are 
abnormalities secondary to the elevated plasma glucose, so-called glucose toxicity. 
Years before the diagnosis of type 2 diabetes mellitus, patients already might have signs 
of insulin resistance. The effect of insulin is deranged and the intake of glucose into 
cells is decreased. To compensate this, the pancreas produces more insulin. Over time 
the insulin producing cells in the pancreas deplete, which leads to elevated blood 
glucose levels and the onset of diabetes. Over the years the production of insulin from 
the pancreas deteriorates further and in the end the use of exogenous insulin is needed.  
 
About one third of all people have a genetic tendency for diabetes. If one of the parents 
has type 2 diabetes mellitus, the risk of the child to fall ill is 40%, and if both of the 
parents have type 2 diabetes mellitus, the risk of the child to fall ill is 70% (Groop and 
Tuomi 1997). If normal weight and physical activity are maintained, the genetic burden 
seldom leads to the onset of diabetes (Tuomilehto 2001). However, abdominal obesity 
and lack of exercise easily trigger type 2 diabetes mellitus. On the other hand, a weight 
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loss of only a few kilograms can prevent or delay the onset of diabetes for many years. 
Caloric reduction and regular exercise showed a 58% reduction in the progression to 
diabetes in people with impaired glucose tolerance (Knowler et al. 2002). The risk 
factors causing type 2 diabetes mellitus are obesity, especially abdominal obesity, 
decreased glucose tolerance, gestational diabetes, lack of exercise, a family burden, high 
age, metabolic disorder, a fatty diet, and smoking (Lyssenko et al 2008; Järvelä et al. 
2006). Many patients having type 2 diabetes mellitus also suffer from the metabolic 
disorder. Especially people with one or more risk factors for type 2 diabetes mellitus 
should pay special attention to life style changes. 
 
Type 2 diabetes mellitus is difficult to diagnose since there are no radical symptoms 
included and thus it has often been latent for years before the diagnosis (Harris 1993). 
Usually type 2 diabetes mellitus is diagnosed by chance during routine doctor’s 
appointments or when diabetic complications appear. By that time the disease may 
already have caused damage in the body and many complications of type 2 diabetes 
mellitus may be present (UKPDS 1990a). These are for example retinopathy, 
nephropathy and neuropathy. If diabetes is diagnosed early, the risk of complications is 
smaller (Colagiuri et al. 2002). In Finland, type 2 diabetes mellitus is diagnosed when 
the fasted blood glucose concentration (fP-gluk) is greater than 7.0 mmol/L (or 11 
mmol/L with clear diabetic signs) or when the two-hour value of the glucose tolerance 
test is more than 11 mmol/L or when HbA1c exceeds 6.5% (Käypä hoito 
recommendation 2011). A person is said to be prediabetic if the two-hour value is 
between 7.8-11.0 mmol/L and the state is called Impaired Glucose Tolerance (IGT). If 
the fasted blood glucose value is slightly elevated (6.1–6.9 mmol/L), the state is called 
Impaired Fasting Glucose (IFG). A raised amount of glycosylated glucose (HbA1c) in 
blood is a sign of elevated blood glucose values during a longer time.  
 
2.3 Other subtypes of diabetes mellitus 
 
The main types of diabetes are type 1 and type 2 diabetes mellitus, formerly known as 
juvenile diabetes and adult-onset diabetes (WHO 1999). However, diabetes can be 
divided into several etiological subgroups. Type 1 diabetes, Maturity Onset Diabetes of 
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the Young (MODY), Latent Autoimmune Diabetes of Adults (LADA) and gestational 
diabetes will be described in more detail. The boundaries between different types of 
diabetes are very hazy and many patients have features of several types. The disease can 
also change over time. 
 
Type 1 diabetes is the second most common type of diabetes in Finland (Reunanen 
2006). About 45 000 patients have type 1 diabetes. The cause of type 1 diabetes is the 
destruction of insulin producing islets of Langerhans, which leads to depletion of 
insulin and thus rise of blood glucose concentration (WHO 1999). Type 1 diabetes can 
be idiopathic or it can be caused by an autoimmune reaction. The cause of the more 
common autoimmune type is still unknown. The only treatment for type 1 diabetes is 
the use of exogenous insulin. Although more than 85% of patients with type 1 diabetes 
do not have a family history for the disease, the onset of type 1 diabetes is strongly 
influenced by genetic predisposition (Steck and Rewers 2011). If one child in the family 
has type 1 diabetes, the risk of the other children to fall ill is 5-10%. If father has 
diabetes, child has a risk of approximately 12% and if mother has diabetes, a risk of 6% 
to fall ill by the age of 20 years.  
 
LADA is similar to type 1 diabetes mellitus characterized by slow onset and some 
features of type 2 diabetes mellitus (Turner et al. 1997; Tuomi et al. 1999). The criteria 
for LADA have been suggested to be adult age at onset (>35 years), presence of 
circulating glutamic acid decarboxylase (GAD) antibodies and absence of a requirement 
for insulin at diagnosis. LADA accounts for about 10% of all cases of diabetes 
(Niskanen et al. 1995). 
 
Less than 5% of subjects with diabetes have MODY (Velho and Froguel 1998). This 
disease is inherited dominantly meaning that if one of the parents has MODY, half of 
the children develop it (Tattersall and Fajans 1975). MODY develops already at young 
age and usually the patients are normal weight (Velho and Froguel 1998). There are 
many types of MODY. Usually the blood glucose concentration is only mildly elevated 
and it can be treated by diet or using oral diabetic medication. Some MODY types 
require use of exogenous insulin at later age. 
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Gestational diabetes means the elevation of blood glucose concentration during 
gestation (Ali and Dornhorst 2011). This is caused by insulin resistance and depleted 
insulin secretion, and it might be fatal for the fetus. The most important treatment of 
gestational diabetes is a healthy diet but insulin treatment is also used when needed. 
Blood glucose concentrations normalize after labor but if untreated, these women are in 
danger of developing diabetes. For example in the study of Järvelä et al. (2006), 4.6% 
of women with gestational diabetes developed type 1 and 5.3% type 2 diabetes mellitus 
during six following years.  
 
Diabetes can as well be caused by secondary reasons such as infections, diseases of the 
exocrine pancreas, endocrinopathies or genetic defects in insulin action (WHO 1999). 
Also drugs or chemicals can induce diabetes. 
 
2.4 Chronic complications of diabetes 
 
Type 2 diabetes mellitus is associated with severe and disabling comorbidities. High 
blood glucose concentrations increase the risk of diabetic micro- and macrovascular 
complications (UKPDS 1998a; Stratton et al. 2000; Holman et al. 2008 a). The risk of 
complications can roughly be evaluated by measuring the values of glycosylated 
hemoglobin (glycohemoglobin, HbA1c), which reflects the long-term glucose balance of 
blood (Stratton et al. 2000). According to Stratton and co-workers each 1% reduction in 
mean HbA1c was associated with reductions in risk of 21% for any end point related to 
diabetes, 21% for deaths related to diabetes, 14% for myocardial infarction, and 37% 
for microvascular complications. The lowest risk is in the normal range of HbA1c 
(HbA1c values <6.0%). 
 
The effort to keep glycemia near normal should be maintained by a combination of diet, 
exercise and drug therapy (UKPDS 1990b; Turner et al. 1999; Manley et al. 2000). The 
strict control of blood pressure is also important because it helps preventing the diabetic 
complications (UKPDS 1998a; UKPDS 1998b; Adler et al. 2000). It is expected that 
the incidence of diabetic complications will be reduced by periodic monitoring of 
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glycemic parameters and by appropriate treatment (Holman et al. 2008a; Matthews et 




In diabetic nephropathy excessive albumin is filtrated into urine. Almost 20% of all 
patients diagnosed with type 2 diabetes mellitus already have symptoms of 
microalbuminuria (Cull et al. 1993). Untreated microalbuminuria might turn into overt 
proteinuria and eventually renal disease (Retnakaran et al. 2006). A small amount of 
protein in urine is harmless but greater amounts cause among other things nephritic 
syndrome and kidney impairment. Dialysis or a kidney transplant might be needed 
(Adler et al. 2003). Subjects with nephropathy also have a greater risk of dying due to 
cardiovascular reasons. The progression of diabetic nephropathy can be prevented or 
slowed down with medication (Retnakaran et al. 2006). Especially hypertension and 
hyperglycemia need to be controlled. Angiotensin converting enzyme inhibitors and 
angiotensin II receptor blockers have been shown to have renoprotective effects and to 
prevent the development of microalbuminuria in subjects with diabetes and 
hypertension (HOPE 2000; Parving et al. 2001; Ruggenenti et al. 2006). Smoking, 
heredity and hyperlipidemia are some of the risk factors for diabetic nephropathy 
(Retnakaran et al. 2006). 
 
2.4.2 Cardio vascular disease 
 
Arteriosclerosis and diseases attached to it, like heart failures, strokes and cerebral 
bleedings, are 2-3 times more common among patients with diabetes than in the rest of 
the population (Gu et al. 1998). Cardiovascular disease (CVD) is the major cause of 
death in people with diabetes, accounting in most populations for 50% or more of all 
diabetes fatalities (Turner et al. 1998). CVD is associated with typical features in type 2 
diabetes mellitus patients: increased HbA1c, fasting plasma glucose concentration, 
systolic blood pressure, triglyceride concentration, increased concentrations of low-
density lipoprotein cholesterol, decreased concentrations of high-density lipoprotein 
cholesterol and a history of smoking. The risk of CVD can be reduced using routine 
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anticoagulation medication therapy and an efficient antihypertensive medication (Davis 




Retinopathy is an illness of the retina. Retinopathy manifests among other things as 
intraretinal or -vitral bleeding, microinfarctions, angiogenesis and retinal dislocation. 
These can lead to temporary or lasting visual disturbances. Regular observations need to 
be done for patients with type 2 diabetes mellitus to discover already the early changes 
in the eyes (Kohner et al. 1999). Microaneurysms are the first clinically recognized 
signs and they strongly predict the onset of diabetic retinopathy. About every third of 
type 2 diabetes mellitus patients have retinopathy at diagnosis (Kohner et al. 1998). The 
most important cause for the retinopathy is the high blood glucose level, but other risk 
factors are hypertension and low serum insulin level. Tight blood pressure control 
prevents the risk of clinical complications from diabetic retinopathy (Matthews et al. 





The cause of diabetic neuropathy is not known. Neuropathy causes aches, muscular 
debility and numbness. It is thought that neuropathy may be caused by excessive 
glucose piling up in the nerves and then turning into sorbitol, which causes swelling and 
disturbs the function of the nerves (Ziegler 2006). Diabetic neuropathy can be 
autonomic or somatic. Somatic neuropathy damages sensory nerves or motor nerves. 
Autonomic neuropathy affects for example the bowel movements. When the circulation 
and the sense of touch in the lower limbs deteriorate, it may cause difficult long-term 
wounds and infections. Even amputation might be needed and it is one of the most 
common reasons for the lower limb amputations (Abbott et al. 1998). Approximately 
16-26% of all patients with diabetes develop chronic neuropathic pain (Daousi et al. 
2004). Poor glycemic control is a risk factor for diabetic neuropathy in type 2 diabetes 
mellitus and thus a constant treatment of hyperglycemia is essential for the prevention 
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of neuropathy (Adler et al. 1997). Other risk factors are age and height (Adler et al. 




3 MEDICATION OF TYPE 2 DIABETES MELLITUS 
 
One of the main goals in the treatment of diabetes is to normalize the blood glucose 
levels. This improves the condition of the patient and effectively prevents diabetic acute 
and chronic complications (Holman et al. 2008a). The target values in the treatment of 
type 2 diabetes mellitus in Finland are < 7.0% for HbA1c, 4-6 mmol/L for fasting 
plasma glucose and < 8 mmol/L for postprandial plasma glucose (circa two hours after) 
according to Käypä hoito recommendations (2011). Type 2 diabetes mellitus patients 
have a significantly higher risk of atherosclerosis and strokes (Gu et al. 1998). It is very 
important to prevent these states. A healthy diet, exercise and weight loss have a 
positive effect on the blood glucose levels and the risk of strokes and atherosclerosis 
(Manley et al. 2000). In addition to these life style factors, there are several medications 
available (Table 1). The drugs mentioned here are all available on the Finnish market. 
In addition to antihyperglycemic medication, type 2 diabetes mellitus patients typically 
also have medicines for hypertension and cholesterol and a low-dose acetylsalicylic acid 
for the prevention of thrombi. These additional medications reduce the risk of diabetic 
complications (UKPDS 1998a; UKPDS 1998b; Davis et al. 1999; Adler et al. 2000). 
 
The first medication, in addition to life style changes, to be used in the treatment of type 
2 diabetes mellitus in Finland is metformin (Käypä hoito recommendations 2011). 
Metformin treatment will usually be started already during the diagnosis phase and after 
3-6 months the efficiency of the treatment will be evaluated. Metformin and the life 
style changes will be continued, but if the HbA1c value is more than 6.5%, an additional 
medication will be added. If the symptoms are mild, another oral hypoglycemic agent 
will be chosen, but if the symptoms are severe, insulin or an incretin mimetic treatment 
will be started. If HbA1c value after this exceeds 6.5%, a third oral agent will be added 
or, alternatively, insulin or incretin mimetic will be started at this point. If metformin 
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and two oral agents will not keep the HbA1c value under 6.5%, insulin or an incretin 
mimetic treatment will still be added. If the HbA1c value is more than 7%, an enhanced 
insulin treatment is needed. 
 
Table 1. Drugs for type 2 diabetes mellitus available on Finnish market. 










α-glucosidase inhibitors Acarbose 
 Miglitol 
  
Thiazolidinediones (glitazones) Pioglitazone 
 Rosiglitazone 
  




Incretin mimetics Exenatide 
 Liraglutide 
  






The only biguanide on the Finnish market is metformin. Phenformin and buformin were 
withdrawn from the market in most countries due to toxic effects (Williams and Palmer 
1975). The mechanism of action of metformin is not completely known. It seems to 
lower the blood glucose concentrations by preventing the gluconeogenesis (generation 
of glucose) in the liver (Hundal et al. 2000) and by enhancing the insulin sensitivity of 
muscles by enhancing the glucose intake and metabolism (Nosadini et al. 1987). 
Metformin might also slow down the rate of absorption of glucose from the small 
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intestine. Metformin might help reduce weight (Morgan et al. 2011) and it also lowers 
the serum triglyceride and cholesterol levels (Landin et al. 1991; DeFronzo et al. 1995). 
It also might lower the elevated blood pressure (Landin et al. 1991). In the Diabetes 
Prevention Program study, metformin reduced the risk of progression from impaired 
glucose tolerance to type 2 diabetes mellitus by 31 % compared to placebo (Knowler et 
al. 2002). 
 
The most common side effects of metformin are abdominal, such as lack of appetite, 
pain and diarrhea (DeFronzo et al. 1995). The absorption of vitamin B12 and folate often 
decrease during metformin therapy but that rarely causes clinical problems. Metformin 
absorbs slowly from the small intestine and the bioavailability is only 50-60 % 
(Pentikäinen et al. 1979; Tucker et al. 1981). Metformin has a volume of distribution of 
63-276 litres, it does not bind to the plasma proteins and it is secreted unchanged to the 
urine. Metformin clearance is significantly affected by the renal clearance. The plasma 
half-life of metformin is 1.5-4 hours. Metformin binds to red blood cells and the half-




Sulphonylureas (glibenclamide, glimepiride and glipizide) lower the blood glucose 
concentration by activating endogenous insulin production in the pancreas (Rendell 
2004). They act by binding to the sulphonylurea receptors 1 (SUR1) located near the 
ATP-dependent K
+
-channel on -cells and inhibit potassium ion efflux through the 
channel like glucose. This eventually leads to the release of insulin. A long-term 
sulphonylurea treatment improves the impact of insulin in the liver, adipose and 
muscular tissues (Kolterman and Olefsky 1984). It is not known, however, whether this 
is caused by the improved glucose metabolism or directly by the drug, possibly through 
an extrahepatic mechanism. The most important of the scarce side effects of 
sulphonylureas is hypoglycemia (Rendell 2004). Irritation in the digestive tract and liver 
dysfunctions are also possible. Sulphonylureas also cause weight gain. All 
sulphonylureas absorb well and relatively fast from the digestive tract. They bind 
relatively strongly to proteins in the serum and they are eliminated by metabolism in the 
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liver. Their elimination half-life varies from 3 (glipizide) to 10 hours (glibenclamide) 




Glinides (repaglinide and nateglinide) are novel insulin secretagogues with a similar but 
slightly different mechanism of action as the sulphonylureas (Balfour and Founds 1998; 
Dunn and Faulds 2000). Nateglinide binds at the same site in the -cells on the SUR1-
receptor as the sulphonylureas, whereas repaglinide binds at a different but nearby site 
causing the closure of ATP-dependent K
+
-ion channels. Glinides improve the prandial 
early-phase insulin secretion and reduce the post-prandial glucose peaks in blood. They 
absorb rapidly and act fast and effectively but are quickly eliminated. Due to this, the 
insulin levels between meals are normal and thus the risk of hypoglycemia is smaller. 
The elimination half-life of glinides is only approximately 1 hour. Glinides are almost 
entirely metabolized. The most important but scarce side effect of glinides is 
hypoglycemia. 
 
3.4 -glucosidase inhibitors  
 
-glucosidase inhibitors (such as acarbose) competitively and reversibly prevent -
glucosidase enzyme in the mucous membrane of small intestine (Bischoff 1994). -
glucosidase enzyme chops prandial carbohydrates into monosaccharides. This inhibition 
delays the cleavage of large unabsorbable carbohydrates into absorbable 
monosaccharides and thus lowers the postprandial blood glucose concentration peak. 
Fasting blood glucose values are not significantly changed. In the Study to Prevent 
Noninsulin-Dependent Diabetes Mellitus (STOP-NIDDM) trial, acarbose reduced the 
risk of progression from impaired glucose tolerance to type 2 diabetes mellitus 
(Chiasson et al. 2002). Acarbose also led to a remarkable reduction in the incidence of 
cardio vascular diseases and hypertension (Chiasson et al. 2003). Only 1-2 % of 
acarbose is absorbed and therefore systemic side effects are scarce (Holman et al 1999). 





Thiazolidinediones (pioglitazone, rosiglitazone), also known as glitazones, lower the 
blood glucose concentration by reducing insulin resistance in the adipose tissue, skeletal 
muscles and liver (Day 1999). They are agonists of the peroxisome proliferator 
activated receptor PRAR-receptor in the nucleus and by activating the receptor they 
regulate the expression of several genes involved in glucose and lipid metabolism. 
Glitazones increase peripheral glucose disposal for example by increasing the glucose 
uptake and decrease hepatic glucose output by reducing gluconeogenesis and 
glycogenolysis. Glitazones mostly have a positive effect on the lipid metabolism (King 
2000). Pioglitazone reduces low-density lipoproteins (LDL) and triglycerides whereas 
rosiglitazone slightly increases them. Pioglitazone also increases high-density 
lipoproteins (HDL) but rosiglitazone has no effect on it. Glitazones cause weight gain 
and edema as side effects. They also cause decreased bone mineral density in both men 
and women, which is a risk factor for fractures (Yaturu et al 2007, Scwarz and 
Sellmeyer 2008). Pioglitazone absorbs fast and it strongly binds to the plasma proteins. 
Half-life of pioglitazone in plasma is approximately 5 hours. In 2010 Food and drug 
administration (FDA) recommended that rosiglitazone would be withdrawn from the 




Gliptins or dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, vildagliptin, 
saxagliptin) are a novel class of type 2 diabetes mellitus drugs. They prevent the activity 
of the incretin hormones-degrading DPP-4 enzyme (Ahrén 2009). GLP-1 (glucagon-like 
peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are endogenous 
incretin hormones secreted in the gastrointestinal tract (Baggio and Drucker 2007). 
GLP-1 and GIP both stimulate insulin secretion from the pancreas and GLP-1 also 
inhibits the release of glucagon from the pancreas. Native GIP and GLP-1 are quickly 
degraded by DPP-4 enzyme. Inhibition of DPP-4 enzyme prolongs the effect of GLP-1 
and GIP in the system and enhances the glycemic control (Ahrén 2009). Gliptins thus 
lower blood glucose values. Because GLP-1 and GIP are secreted in the presence of 
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glucose, secretion of insulin is mainly stimulated after meals, and the risk of 
hypoglycemia using DPP-4 inhibitors between meals is therefore minimal. Due to the 
recent availability of gliptins, the effects of the long-term use are not known well.  
 
Sitagliptin, vildagliptin and saxagliptin are all very selective and strong DPP-4 
inhibitors (Ahrén 2009). They are all safe and well tolerated. Adverse effects, including 
hypoglycemia, headache and different infections, are very rare. Gliptins do not have any 
effect on body weight. Gliptins absorb fast and their biological availability is good 
(Scheen 2010a). Gliptins do not significantly bind to plasma proteins. Sitagliptin is 
mostly secreted unchanged into the urine and only a small part is metabolized whereas 
metabolism is the main elimination route of vildagliptin. Saxagliptin is eliminated in the 
liver and kidneys. The elimination half-life of gliptins varies from 2-3 hours for 
vildagliptin and saxagliptin to 12.5 hours for sitagliptin. 
 
3.7 Incretin mimetics  
 
Incretin mimetics (exenatide, liraglutide) are GLP-1-analogs, which bind to GLP-1-
receptors and act as endogenous GLP-1 (Kolterman et al. 2005; Ryan and Hardy 2011). 
The structures of exenatide and liraglutide are similar with the GLP-1 but they are 
modified in a way, which enables them to absorb slower and affect significantly longer 
before cleavage by DPP-4 enzyme. Incretin mimetics reduce postprandial and fasting 
blood glucose levels in type 2 diabetes mellitus patients by increasing the secretion of 
insulin after meals. Due to their protein structure incretin mimetics can not be 
administered orally but require a subcutaneous injection once or twice a day.  
 
Exenatide and liraglutide are slowly absorbed after a subcutaneous injection and they 
both strongly bind to plasma proteins (Kolterman et al. 2005; Ryan and Hardy 2011). 
The exact route of elimination is not clear. As side effects incretin mimetics cause 
nausea, vomiting and mild hypoglycemia. Acute pancreatitis and acute necrotizing or 
hemorrhagic pancreatitis has been found in patients receiving incretin mimetics but the 
causality is not clear. Exenatide and liraglutidi have an advantage in producing a 
significant weight loss. The mechanism is thought to be their ability to slow gastric 
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emptying and reduce food intake. Incretin mimetics might also reduce blood pressure 




Type 2 diabetes mellitus is a progressive disease, which as time goes on is more 
challenging to manage (Peters 2011). As the production of the endogenous insulin 
production depletes, most patients with type 2 diabetes mellitus eventually will start 
using exogenous insulin. Since insulin is a peptide hormone, it decomposes if it is 
administered orally and insulin is thus administered subcutaneously or intramuscularly. 
Exogenous insulin possesses a similar effect in the body as the endogenous insulin. 
Insulin is metabolized by insulinase enzyme. All insulin products nowadays are fully or 
at least partly synthetic. The differences between insulin products are in the length of 
action, Cmax, origin and formulation. The most common side effect of insulin is 
hypoglycemia. Typical are also reactions in the injection site and weight gain. 
 
3.9 Guar gum 
 
Guar gum is a gel forming fiber product, which activates in the gastrointestinal track 
and slows down the absorption of carbohydrates (Uusitupa et al 1990). In combination 
with other diabetic medication it lowers the postprandial blood glucose concentration 
peaks. It also lowers the serum cholesterol levels. Guar gum can cause diarrhea and 
flatulence as side effects. 
  
 
4 ANIMAL MODELS OF TYPE 2 DIABETES MELLITUS 
 
Animal models used for the research of type 2 diabetes mellitus are mostly rats and 
mice (Srinivasan and Ramarao 2007). Rodents are applicable because they are small, 
easily available and inexpensive and they reproduce quickly. No known single animal 
species is exactly identical to human diabetes in all its complexity. However, different 
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models can be used as tools for studying the onset, the mechanisms and the treatment of 
type 2 diabetes mellitus. 
 





I Spontaneous or 
genetically ob/ob  mouse Cohen diabetic rat
 derived diabetic animals db/db mouse GK rat
KK mouse Torri rat
KK/A
y
 mouse (Akita) mutant mouse
NZO mouse









II Diet/nutrition induced Sand rat ---
diabetic animals C57/BL 6J mouse
Spiny mouse
III Chemically induced 
diabetic animals
GTG treated obese mice Low dose ALX or STZ adult rats, 
mice etc.
Neonatal STZ rat
IV Surgical diabetic animals VMH lesioned dietary obese 
diabetic rat
Partial pancreatectomized animals 
e.g. dog, primate, pig and rats
V Transgenic/knock-out 
diabetic animals
β3 receptor knockout mouse Transgenic or knock out mice 
involving genes of insulin and 
insulin receptor and its 
components of downstream insulin 
signaling e.g. IRS-1, IRS-2, 
GLUT-4, PTP-1B and other
Uncoupling protein (UCP1) 
knock-out mouse
PPAR-γ tissue specific knockout 
mouse
Glucokinase or GLUT 2 gene 
knockout mice
Human islet amyloid polypeptide 
overexpressed rat (HIP rat)
KK, Kuo Kondo; KK/Ay, yellow KK obese; VMH, ventromedial hypothalamus; ZDF, Zucker diabetic fatty; NZO, New Zealand
obese; TSOD, Tsumara Suzuki obese diabetes; SHR/N-cp, spontaneously hypertensive rat/NIH-corpulent; JCR, James C Russel;
OLETF, Otuska Long Evans Tokushima fatty; GTG, gold thioglucose; ALX, alloxan; STZ, streptozotocin; GLUT-, glucose transporter;
IRS, insulin receptor substrate; GK, Goto-Kakizaki; PPAR, Peroxisome proliferator activated receptor, PTP, phosphotyrosine
phosphotase; ALS, alloxan sensitive
Type 2 diabetic models
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There are several ways to induce diabetes and to create an animal model of diabetes. 
The disease and the symptoms might be spontaneously developed, they might be 
generated using a special diet or they can be caused by chemical exposure or by surgical 
manipulations (Srinivasan and Ramarao 2007). In recent years, a number of new models 
have also been developed using genetic engineering or molecular biological techniques 
including transgenic and knock-out mice. Different animal models of diabetes have 
been mentioned in Table 2. Some rat models are then introduced as examples. 
 
4.1 Chemically induced rat model of diabetes 
 
One of the simplest and most common ways to generate diabetes is the induction using 
chemicals. Diabetes can be induced using many chemicals, such as vacor and dithizone, 
but alloxan and streptozotocin are the most common ones (Rees and Alcolado 2004). 
Chemical induction of diabetes is widely used because it is economical and easy. 
 
Alloxan induced diabetes was first discovered incidentally in 1943 when Dunn et al. 
(1943) were studying the effects of different substances on the kidneys of rabbits. 
Alloxan first caused low blood glucose values in the rabbits but shortly after a 
remarkable hyperglycemia. Histological studies showed significant necrosis of the 
pancreatic islets. Alloxan selectively destroys pancreatic β-cells (Rerup 1970). Alloxan 
induced diabetes causes the classical symptoms of human diabetes like acidosis, 
polyphagia, hyperglycemia, polydipsia, polyuria, glucosuria and ketonuria (Srinivasan 
and Ramarao 2007). Alloxan treated animals also develop diabetic complications such 
as neuropathy, retinopathy and cardiomyopathy. In addition to rabbits, alloxan has also 
been discovered to induce diabetes in the cat, dog, hamster, man turtle, monkey, mouse, 
pigeon, rat and sheep (Rerup 1970).  
 
Alloxan induced diabetes is not, however, permanent (Lazarow 1952, Bunnag et al. 
1967). Especially if the alloxan dose is too small, the effect of alloxan can be overruled 
by the ability of the pancratic cells to regenerate. This sets limits to the duration of the 
studies using alloxan rats. Another disadvantage in this model is that the mechanism of 
alloxan induced diabetes is very different from human diabetes (Lukens 1948). The 
symptoms are similar but the disease is not. 
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Because of the limitations of alloxan, streptozotocin has recently become more common 
for induction of diabetes in laboratory animals. A single large dose of streptozotocin 
leads to the development of type 1 diabetes, but several small doses neonatally or soon 
after birth produce type 2 diabetes mellitus in the adult age (Portha et al. 1974). 
Streptozotocin specifically causes irreversible necrosis in the β-cells leading to 
reduction in β-cell mass and insulin deficiency (Junod et al. 1967). At 8-10 weeks of 
age rats neonatally treated with streptozotosin reflect mild basal hyperglycemia, 
impaired glucose tolerance (Portha et al. 1979) and a loss of -cell sensitivity to glucose 
(Giroix et al. 1983). Streptozotocin causes diabetes in the dog, guinea pig, hamster, 
monkey, mouse and rat (Rerup 1970). Streptozotocin can also be used together with 
nicotinamide (Masiello et al. 1998). A right amount of nicotinamide prior to 
streptozocin injections to rats protects the pancreatic -cells from a total destruction. 
With the 40% preservation of the pancreatic insulin stores, the produced stage better 
resembles human type 2 diabetes mellitus than with the streptozocin given alone. A too 
large amount of nicotinamide reverses the effects of streptozocin.  
 
4.2 Spontaneous or genetically derived rat model of diabetes 
 
Goto-Kakizaki (GK) rat is a widely used animal model for the research of type 2 
diabetes mellitus and the comormidities related to it (Portha 2005). GK rat is used as an 
animal model in the experimental part of this study because it is well characterized and 
it is suitable for the study of the test items. Another suitable model would have been 
Zucker Diabetic Fatty (ZDF) rat. Thus GK and ZDF rats are described and compared 
here in more detail than the other rat models of diabetes. 
 
4.2.1 Goto-Kakizaki rats 
 
The Goto-Kakizaki (GK) rat strain was developed in Japan, Sendai at Tohoku 
University by Goto and Kakizaki in 1973 (Goto et al. 1976). They performed an oral 
glucose tolerance (OGT) test to 211 normal Wistar rats and chose 18 of them having a 
reduced glucose tolerance. They mated them and continued by selective breeding using 
glucose tolerance as the selection index. After the 10
th
 generation all of the offspring 
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had a diabetic glucose tolerance test and the diabetic state became stable after the 30
th
 
generation (Goto et al. 1988). The first signs of glucose intolerance in GK rats are seen 
at the age of two weeks but the stage becomes prominent at 8 weeks of age (Goto et al. 
1988).  
 
GK rats do not have a tendency for obesity (Goto and Kakizaki 1981). In fact, they are 
slightly leaner than the sex- and age-matched normal Wistar rats. The progression of the 
diabetic stage of GK rats is shown in Table 3. The genetic background of GK rats has 
been studied in order to better understand the mechanism of type 2 diabetes mellitus 
(Galli et al. 1996, Gauguier et al. 1996). Already Goto and coworkers (1981) suspected 
that the inheritance of type 2 diabetes mellitus in GK rats is polygenic, but is was shown 
when Gauguier and coworkers (1996) found 6 independent loci responsible for example 
for hyperglycemia, glucose intolerance and altered insulin secretion.  
 
Table 3. Progression of diabetic state in Goto-Kakizaki rats. Modified from Movassat et 
al. 2007 
 FETAL SUCKLING ADULT 
-cell mass Reduced  Reduced  Reduced 
Blood glucose 
concentration 








  Increased 
Insulin resistance   Hepatic after 4 weeks, peripheral 
after 8 weeks 





In 1988, a colony of GK rats was started in Paris using breeding pairs from the 35
th
 
generation of the original colony (Portha et al. 1991) and in 1980 a colony was started 
in Stockholm using pairs from the 40
th
 generation (Abdel-Halim et al. 1993). There are 
small differences between the different colonies of GK rats but the characteristics are 
very similar (Portha et al. 1991, Portha 2005). All GK rats have a mild hyperglycemia 
as early as 4 weeks after birth with elevated non-fasting blood glucose concentrations 
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(10-14 mmol/L) compared to Wistar control rats (6-8 mmol/L). Already at an early age 
(4 weeks old) GK rats show some signs of insulin resistance in the liver (Picarel-
Blanchot et al. 1996). At an older age (8 weeks old) GK rats show remarkable insulin 
resistance also in the skeletal muscles and the adipose tissue (Bisbis et al. 1993). The 
non-fasting plasma insulin levels of GK rats are also deranged. Murakawa et al. (2002) 
reported hyperinsulinemia in GK rats at the age of two months and hypoinsulinemia at 
the age of 18 months, although according to Portha et al. (1991) GK rats were 
hyperinsulinemic during the entire 32-week follow-up. The glucose-induced insulin 
release in GK rats is sluggish and delayed, and the total concentration of insulin in 
blood after a glucose load is significantly smaller than in Wistar rats (Goto et al. 1981). 
Both the early and the late phase of glucose-induced insulin release, which are also seen 
in humans, are decreased in GK rats (Goto et al. 1988). The impairment of glucose-
induced insulin response as well as the glucose intolerance have maintained relatively 
stable over the generations in all different colonies (Portha 2005).  
 
Differences between colonies have, however, been seen in -cell number, insulin 
content and islet metabolism. Decreased size of the pancreatic islets and reduced 
number of -cells in GK rats were described already by Goto et al. in 1988. Goto and 
Kakizaki (1981) also reported earlier that the shape of the islets of the pancreata of GK 
rats changed from round to irregular starfish shape by the age of four months. Movassat 
et al. (1997) showed that in the colony of Paris, the relative volume and the total mass 
of the -cells in GK rats are significantly decreased already at the neonatal age. The 
relative volume represents only 38% and the total mass only 23% of the values of age-
related control rats. Movassat et al. also noticed that the pancreatic insulin contents 
were significantly smaller in GK rats, only 23% of the value of control rats. The 
pancreatic defects remain prominent also at the adult age. The reason for these defects is 
probably a gestational metabolic impairment, which leads to inadequacy of the 
pancreatic growth factors necessary for the growth and development of fetal pancreatic 
cells. As a result, the neogenesis and the proliferation of β-cells is decreased. Due to 
chronic exposure to hyperglycemia, a secondary (acquired) loss of β-cell differentiation 
will be seen at a later age (glucotoxicity). Glucotoxicity possibly then leads to the 
impaired glucose-induced insulin release (Picarel-Blanchot et al. 1996). In the adult GK 
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rats of the Stockholm colony, however, decreased as well as normal pancreatic insulin 
contents and normal islet -cell density have been reported  (Abdel-Halim et al. 1993, 
Östenson et al. 1993, Guenifi et al. 1995). This suggests that different local breeding 
environments could have an effect on the characteristics of GK rats or that new genetic 
changes would have occurred inside the colonies (Portha 2005). Nowadays there are 
also GK rat colonies in UK, USA and Portugal. 
 
In 1978 Yagihashi et al. studied the first diabetic complications in GK rats. They 
discovered that the GK rats implement greater thickening of the glomerular basement 
membrane than control rats. Thickening of the glomerular basement membrane 
becomes prominent with age but it also is an early sign of diabetic nephropathy (Mauer 
et al. 1984). In 1979 Yagihashi et al. studied the formation of glomerular lesions in GK 
rats and the results indicated that the development of diabetic glomerulopathy might be 
destined very early in life of the spontaneously diabetic rats perhaps by their genes. 
Glomerular changes in GK rats have later been studied for example by Phillips et al. 
(2001), Sato et al. (2003) and Schrijvers et al. (2004). Phillips et al. (2001) and Sato et 
al. (2003) suggested that the renal structural changes might be induced by the constant 
hyperglycemia. GK rat has been noticed to implement similar glomerular changes as 
seen in human type 2 diabetes mellitus (for example glomerular hypertrophy and a 
decline in GFR) at later stage and it can be used as a model in studying renal structures 
and functional changes (Schrijvers et al. 2004). Also diabetic neuropathy has been 
discovered in GK rats (Yagihashi et al. 1982). Yagihashi et al. (1982) reported slowing 
of nerve conduction velocity, axonal atrophy and segmental demyelination as the 
characteristic features of the neuropathy in GK rats. Later Murakawa et al. (2002) 
suggested that peripheral neuropathy in GK rats is caused by the impaired glucose 
tolerance and insulinopenia. Changes in nerve conduction velocity, loss of small 
myelinated fibers and loss of unmyelinated axons could be seen at the age of 18 months 
in their study. GK rats also show signs of diabetic retinopathy at an older age and this 
rat model can be used to study the mechanism of retinopathy in humans (Miyamoto et 




Goto-Kakizaki is a well-characterized rat model of type 2 diabetes mellitus. GK rats 
implement all the typical symptoms of human type 2 diabetes mellitus and also features 
of some diabetic complications seen in humans. GK rats are not obese, hypertensive or 
hyperlipidemic unlike most rat models of type 2 diabetes mellitus. That makes them a 
good model for studying the properties and mechanisms of human type 2 diabetes 
mellitus without the effect of these states.  
 
4.2.2 Zucker Diabetic Fatty rats  
 
Lois and Theodore Zucker first found the Lepr
fa
 mutation in rats in 1961 (Zucker and 
Zucker 1961). Lepr
fa
 is a spontaneous autosomal recessive Leptin receptor gene 
mutation. It leads to obesity, insulin resistance, mild glucose intolerance, 
hyperinsulinemia, hyperlipidemia and moderate hypertension. The discovery of the 
mutation led to the development of Zucker Fatty Rat (ZFR). Zucker fatty rats can be 
used at the research of glucose intolerance, insulin resistance, metabolic syndrome and 
genetic obesity but not type 2 diabetes mellitus. 
 
The Zucker Diabetic Fatty (ZDF) rats derive from the selectively inbred hyperglycemic 
Zucker fatty rats. A mutation first occurred in a colony of outbred Zucker fatty rats in a 
laboratory in Indianapolis, USA in 1974 (Clark et al. 1983) but it was not until the late 
1980`s that Peterson et al. (1990) started breeding Zucker rat model of diabetes 
purposely in bigger scale. ZDF rats carry a genetic defect in the -cell transcription in 
addition to the leptin receptor mutation (Griffen et al. 2001). After ten generations of 
inbreeding all male ZDF rats developed a constant and durable type 2 diabetes mellitus 
(Peterson et al. 1990). ZDF rats are less obese but more insulin resistant than Zucker 
fatty rats. Female ZDF rats only become diabetic if they are fed on a special high-fat 
diet (Etgen and Oldham 2000). Female ZDF rats, thus, usually serve as controls in the 
studies. 
 
Zucker diabetic fatty rats spontaneously develop a diabetic state at the age of about ten 
weeks (Etgen and Oldham 2000). Their muscles first become insulin resistant at around 
7 weeks of age and at around 20 weeks of age they have an overt state resembling 
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human type 2 diabetes mellitus with marked glucose intolerance and hyperglycemia 
(>22 mM, non-fasted). In the early age (4-10 weeks) ZDF rats are hyperinsulinemic but 
later (12- weeks) they become hyperglycemic and hypoinsulinemic. The reduction in 
the insulin levels is caused by the greater -cell death compared to new -cell formation 
in the pancreas between ages 6-12 weeks (Pick et al. 1998). It seems that when the 
hyperinsulinemia starts to fade, the pancreas and the insulin-resistant peripheral tissues 
can no longer compensate the excess amount of glucose produced by the liver and the 
hyperglycemia takes over. The non-diabetic Zucker fatty rats avoid the progression of 
hyperglycemia due to a sustained compensatory hyperinsulinemia.  
 
In addition to type 2 diabetes mellitus, ZDF rats also possess obesity, mild 
hypertension, hypertriglyceridemia and hypercholesterolemia (Peterson 1990). Later in 
life they show symptoms of diabetic nephropathy (Vora et al. 1996), microvascular 
retinopathy (Danis and Yang 1993), neuropathic complications (Shimoshige et al. 2000) 
and impaired wound healing (Slavkovsky et al. 2011). Zucker diabetic fatty rats can be 
used at the research of type 2 diabetes mellitus, glucose intolerance, hyperinsulinemia, 
obesity, impaired wound healing and hyperlipidemia.  
 
4.2.3 Comparison of Goto-Kakizaki and Zucker diabetic fatty rat models 
 
Zucker diabetic fatty and Goto-Kakizaki are both selectively bred rat models for type 2 
diabetes mellitus (Goto et al. 1976; Clark et al. 1983). They are both versatile and 
widely studied models. They both have glucose intolerance and insulin resistance and 
they both also embody symptoms of diabetic comorbidities such as nephropathy and 
neuropathy (Yagihashi et al. 1979; Yagihashi et al. 1982; Vora et al. 1996; Shimoshige 
et al. 2004). The origins of the defects in the animal models are different. In GK rat the 
polygenic changes in -cells originate already from the neonatal age (Movassat et al. 
1997). The proliferation of -cells is not adequate and they are deformed. Pancreatic -
cells in GK rat are thus not able to produce enough insulin. At a later age the beta-cell 
destruction is continued by glucotoxicity. In ZDF rat, the disease is caused by a leptin-
gene mutation and the destruction of -cells only begins after birth (Clark et al. 1983). 
The -cells in the pancreas of ZDF rat are brittle and have a limited ability to endure 
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pressure (Pick et al. 1998). Pancreas compensates the insulin resistance by increasing 
insulin production and this causes pressure to the -cells. The deficit of -cells in ZDF 
rat is thus not caused by the low proliferation or malfunction of -cells, but by the 
massive rate of apoptosis. GK rats are not obese, hypertensive or hyperlipidemic unlike 
most rat models of type 2 diabetes mellitus, also ZDF rats. That makes them a good 
model for studying type 2 diabetes mellitus without the effect of these states. Both rat 
models would have been suitable for studying the chosen test items, gliclazide and 
fosinopril, in the experimental study. Sulphonylureas, such as gliclazide, improve the 
secretion of insulin from the pancreas and diminish the insulin resistance and ACE 
inhibitors, such as fosinopril, possibly enhance the insulin sensitivity (Rendell 2004; 
Chen et al. 1996). Goto-Kakizaki rat model was chosen for its non-obesity and more 
reasonable price. Gliclazide had also been studied on GK rats before and it was thus 
known that gliclazide improves -cell function, increases -cell insulin stores and 




5 DRUG INTERACTIONS 
 
5.1 The significance of drug interactions 
 
Drugs can have a beneficial or a harmful effect on each other’s action. Food, stimulants, 
herbs and health products might also have an impact on the effect and safety of drugs. 
Drug interactions can be divided into pharmacokinetic and pharmacodynamic 
interactions. Not all interactions are clinically significant. More severe drug interactions 
are most likely to occur for drugs with a narrow margin of safety and for drugs used for 
a prolonged period of time (Reimche et al. 2011). The use of several different drugs 
concurrently, alias polypharmacy, also increases the risk of interactions. One group of 
patients prone to polypharmacy is patients with type 2 diabetes mellitus. In addition to 
antidiabetic medicine, patients with type 2 diabetes mellitus also have for example 




Drug interactions are of great importance not only for the individuals concerned, but 
also for the entire community. Drug interactions cause significant costs through 
unnecessary medications and increased number of hospitalizations. For example 
McDonnell and Jacobs (2002) reported that 26 % of the studied 437 hospitalizations 
were due to drug-drug interactions. The probability of drug interactions increases with 
the growing number of drugs used per person and the number is the single most 
important risk factor for interactions (Reimche et al. 2011). According to a study made 
in the USA the probability for a clinically significant interaction is more than 50% in 
patients using minimum four, but more than 90% in patients using eight concomitant 
medications (Weideman et al. 1998). World Health Organization (WHO) has 
recommended that each patient only had at maximum five concomitant medicines. In 
Kuopio 75+ –study elders aged over 75 years used approximately 7,5 different drugs 
(Jyrkkä et al. 2006). In addition to the number of drugs used, other risk factors for drug 
interactions are age and comorbidities, including renal insufficiency (Reimche et al. 
2011). 
 
Drug interactions have been an essential reason for adverse effects of drugs and for the 
cancellations of drug selling licenses in recent years (SoRelle 1998; Hondeghem et al. 
2011). As a result the pharmaceutical companies have a financial interest to study the 
interaction already early during the development of drugs. If a drug is for example a 
strong inhibitor of some important metabolizing enzyme, the development might be 
discontinued. The authorities have given detailed instructions for the necessary research 
of interactions (U.S. Food and Drug Administration 2006; European Medicines Agency 
2010). For example the features and the target group of the drug guide the design of the 
interaction studies. Comprehensive in vitro and in vivo studies precedes clinical studies. 
If any interactions are found in preclinical studies, they must be certified in clinical 
studies. Most of the drug interaction studies are performed in healthy individuals. 
However, diseases might have an impact on the behavior of drugs in the system. The 
extrapolation of results from interaction studies into clinical situations might thus not be 
straightforward. It is for example well known that kidney diseases reduce the clearance 
of many drugs (Joy 2012). Other diseases might also have an impact on the 
pharmacokinetics of drugs and research on patients is thus needed. 
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5.2 Pharmacokinetic interactions 
 
Pharmacokinetic interactions can be present in any phase of the drug through the 
system. A pharmacokinetic interaction always leads to an altered plasma concentration 
of one of the drugs (Hines and Murphy 2011). This might lead to a stronger or weaker 
effect of this drug. There are also compensatory mechanisms, which might suppress the 
clinical significance of interactions. If a drug, for example, has two pathways of 
metabolism, the inhibition of one can lead to a more efficient use of the other.  
 
The most important route of drug administration is oral. After oral dosing, drugs first 
need to dissolve and then absorb through the lumen of the intestinal tract. There are 
many possible drug-drug interactions during this phase. The drug can, among other 
things, be absorbed by another drug, for example activated charcoal or resins 
(Neuvonen and Olkkola 1984). The transport of the drug through the wall of the bowel 
can also be induced or inhibited by another drug (Endres et al. 2006). A drug can also 
change the pH of the stomach, which can prevent the dissolution and the absorption of 
another drug, or a drug can get chelated with another drug, for example metallic ions 
(Shiba et al. 1992; Tomilo et al. 2006). 
 
After the absorption the drug distributes into the system. During the distribution the 
drug can for example be displaced by another drug from a plasma carrier protein, which 
leads to an increased concentration of unbound drug in the circulation (Panjehshahin et 
al. 1991). Only the unbound fraction of the drug can absorb into the tissues. The 
distribution of a drug can also be affected by transporter proteins, which are in charge of 
taking the drugs into the target tissues (Endres et al. 2006). The action of transporter 
proteins can be induced or inhibited by another drug. Quinidine, for example, inhibits 
the action of P-glycoprotein, an important transporter protein, which for example 
protects the brain by effectively pumping foreign subjects back to the circulation from 
the blood brain barrier (Sadeque et al. 2000). For example loperamide is a substrate of 
P-glycoprotein. The inhibition of P-glycoprotein by quinidine thus leads to a significant 




The next phase of the drug in the system is the metabolism. The purpose of the 
metabolism is to transform lipophilic drugs and foreign matters into more water-soluble 
form for the kidneys and the bile to excrete them out of the system. Metabolism is two-
stage. The most important catalysts in the oxidative phase I metabolism are the 
cytochrome P450 (CYP) enzymes (Pelkonen et al. 2008). Usually, but not always, 
phase I is followed by phase II metabolism where a very polar endogenous conjugate is 
attached to the metabolite from phase I (McCarver and Hines 2002). The more relevant 
and more widely studied part concerning drug interactions is the phase I metabolism. 
 
The most important organ for drug metabolism is the liver, but there are CYP enzymes 
also for example in the wall of the small intestine, the lungs, the heart, the brain and the 
placenta (Pelkonen et al. 2008). Essential parts of drug metabolism are the genetic 
families of CYP enzymes CYP1, CYP2 and CYP3. Diseases, nutrients and some 
stimulants, like caffeine, can also affect the activity of oxidative metabolism. Genetic 
polymorphism in CYP enzymes is relatively common and thus inter-individual 
differences in metabolism can be major. Clinically most important ones are CYP2C9, 
CYP2C19 and CYP2D6. 
 
The inhibition and the induction of cytochrome P450 are the most remarkable 
mechanisms of drug interactions (Pelkonen et al. 2008). The inhibition of the 
metabolism of a drug might lead into increased plasma concentration, accumulation and 
increased side effects or even toxicity. Induction of the metabolism might lead into 
decreased plasma concentrations and possibly to a lack of the effect. In clinical use, 
when a drug seems ineffective, the dose of the drug is increased and other drugs with 
the same indication are added in addition to the original medicine. Induction can thus 
lead to polypharmacy.  
 
Inhibition or induction of metabolism can be significant if a pro-drug is concerned 
(Pelkonen  et al. 2008). For the action of a pro-drug the normal metabolism is essential. 
If the metabolism of a pro-drug into its active form is inhibited the desired action of the 
medicine will not be achieved. If the metabolism of a pro-drug is induced, the 
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concentration of the active drug might increase and the possibility of side effects 
increases.  
 
The CYP enzymes in the wall of the small intestine and the liver have a very important 
role in the first-pass metabolism (Pelkonen et al. 2008). Significant first-pass 
metabolism of a drug can reduce its bioavailability remarkably. If the first-pass 
metabolism is inhibited by another drug, the bioavailability might increase and this can 
lead to dangerously high plasma concentrations of the first drug.  
 
Some of the essential phase II metabolism reactions are glucuronidation, acetylation and 
methylation (McCarver and Hines 2002). These reactions are catalyzed by a large group 
of broad-specificity enzymes, such as uridine 5'-diphospho-glucuronosyltransferase 
(UDP-glucuronosyltransferase). Also conjugative enzyme can be induced or inhibited 
by other drugs. For example rifampicin induces the glucuronidation and thus decreases 
the concentration of for example lamotrigine (Ebert et al. 2000). Polymorphism is also 
common in phase II metabolism enzymes. 
 
The last phase of the drug in the system is the excretion of the drug through the bile or 
the kidneys. In this phase a drug can change the urinal pH or it can change the blood 
circulation in the kidneys, which might prevent or enhance the excretion of another drug 
into the urine (Nilsson et al. 1982; Kristoff et al. 1986). A drug can also inhibit or 
induce the transporters in the kidneys or in the bile and thus lead to faster or slower 
elimination of another drug from the system. For example verapamil increases the half-
life and the plasma concentration of digoxin significantly (Verschraagen et al. 1999). 
Verapamil is an inhibitor and digoxin a substrate of P-glycoprotein. The interaction is 
probably caused by the inhibition of P-glycoprotein by verapamil, which leads to  
decreased tubular secretion of digoxin.  
 
5.3 Pharmacodynamic interactions 
 
A pharmacodynamic interaction leads to a change in at least one drug action without the 
change in the drug concentration (Hines and Murphy 2011). Many drugs bind to a 
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receptor and cause a similar but usually stronger effect than the endogenous transmitters 
in the system. This is called agonism. Some drugs bind to receptors but they prevent the 
binding of the transmitters. This is called antagonism. Antagonism can be competitive 
i.e. an agonist can displace the antagonist from the receptor, or it can be non-
competitive, in which case no amount of agonist can displace the antagonist. Drugs can 
function as antagonists or agonists to each other. This is for example commonly utilized 
in the treatment of drug poisonings. Many antidotes, for example naloxone, work as 
antagonist for the relevant receptors, in this case for opiate-receptor (Dahan et al. 2010). 
Agonism-antagonism can also be harmful. For example some asthma medicines work as 
agonists for adrenergic -receptors whereas many antihypertensive medicines work as 
antagonists for them (Chen et al. 2001). Concomitant use of these medications can 
therefore prevent the effect of both medicines. 
 
Additive interaction means that the effect of the dosed drugs is similar or that they 
affect the same organs. This can lead to increased toxicity (van Dijk et al. 2004). 
Additive interaction can, however, also be useful. For example many antihypertensive 
medicines have a different mechanism of action but the effect on hypertension is 
similar, decreasing (Everett et al. 2008). This can be utilized in the treatment of 
hypertension. Drugs designed for totally different purposes can cause a potentiative 
interaction by affecting the same organs. Typical example of this is the interaction of 
non-selective anti-inflammatory medicines and the selective serotonin reuptake 
inhibitors (Tata et al. 2005). Both drugs have a deteriorating effect on platelet function, 
but the mechanism is different.  
 
5.4 Drug interactions of clinical importance with antihyperglycemic agents 
 
5.4.1 Interactions with antihyperglycemic agents 
 
Patients with diabetes typically use a wide variety of drugs. They have a significant risk 
of interactions due to this polypharmacy (Reimche et al. 2011). Potential interactions 
can occur between different antidiabetic drugs, and between antidiabetic drugs and 
other widely co-administered pharmacological agents (antihypertensive, lipid-lowering 
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and antiplatelet agents). In addition to these, especially agents with a narrow safety 
index (digoxin, warfarin) and those that are known to induce or inhibit the CYP 
enzymes are also in a great risk of causing interactions. Scheen (2005) has written a 
comprehensive article about interactions between antihyperglycemic agents and 
between antihyperglycemic agents and other pharmacological compounds that are 
typically used with diabetes medicines. The article concerns metformin, sulphonylureas, 
thiazolidinediones, -glucosidase inhibitors and glinides. The interactions of gliptins 
are described in a latter article of Scheen (2010b). 
 
In general, only minor drug-drug interactions appear between antihyperglycemic agents 
and antihyperglycemic agents and other drugs (Scheen 2005). For example cimetidine 
competes for a transport system in the renal tubules with metformin. This reduces the 
rate of urinary excretion of metformin. In a study of Somogyi et al. (1987) in healthy 
volunteers cimetidine caused a 50 % increase in the plasma AUC and a 27 % decrease 
in the 24-hour renal excretion of metformin. Incidents of chronic cardiac insufficiency 
have been reported to increase when insulin and rosiglitazone are used concurrently 
(Marceille et al. 2004). The exact mechanism of this interaction is unknown but it 
probably is related to fluid retention induced by rosiglitazone and insulin. A third 
example of the interactions of antidiabetic drugs is between acarbose and digoxin. 
Acarbose has been shown to decrease the absorption of co-administered digoxin (Miura 
et al. 1998). Acarbose reduced the serum level of digoxin by 30-40% and AUC by 40%. 
 
Several antihyperglycemic agents have a pharmacodynamic, blood glucose-lowering 
additive interaction when used simultaneously (Scheen 2005). This effect can be 
utilized in the treatment of type 2 diabetes mellitus, especially because the risk of 
adverse effects does not increase proportionally. Combinations of antidiabetic drugs are 
already widely used. The traditional combination has been metformin-sulphonylurea, 
but new combined therapies are now available, for example metformin plus 
thiazolidinedione and sulphonylurea plus thiazolidinedione. A higher possibility for 
hypoglycemic episodes is present in the co-administration of antihyperglycemic drugs, 
especially those acting through release of insulin, such as sulphonylureas and 
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meglitinide analogues, and for example gliptins (Scheen 2010b). These episodes can, 
however, be prevented with dose corrections. 
 
Cytochrome P450 isoenzymes are strongly involved in the metabolism of the glucose-
lowering drugs and they cause the most important drug-drug interactions. Glinides are 
all metabolized via CYP3A4 enzyme (Scheen 2007b). In addition to CYP3A4, 
repaglinide is metabolized via CYP2C8 and nateglinide via CYP2C9. The metabolism 
of pioglitazone is mainly catalyzed by CYP2C8 and CYP3A4, whereas rosiglitazone is 
metabolized by CYP2C9 and CYP2C8 (Scheen 2007a). DPP-4 inhibitors do not 
interfere with CYP enzymes (Scheen 2010b). The only exception is saxagliptin, which 
is metabolized to an active metabolite by CYP3A4/5. The most important enzyme 
responsible for the metabolism of sulphonylureas is CYP2C9 (Scheen 2005). 
Metformin is not metabolized in humans after oral or intravenous administration but it 
is eliminated by renal excretion. The most relevant pharmacokinetic interaction can be 
found between gemfibrozil, a fibric acid derivative, and repaglinide (Scheen 2005). 
Gemfibrozil inhibits the CYP2C8 enzyme. In a study of Niemi et al. (2003b), 
gemfibrozil increased the plasma AUC of repaglinide by 8-fold and the Cmax by 140%. 
A less significant interaction has been reported between gemfibrozil and rosiglitazone 
(Niemi et al. 2003a). Gemfibrozil raised the plasma AUC of rosiglitazone by 2.3-fold 
and prolonged the elimination half-life of rosiglitazone from 3.6 to 7.6 hours (Niemi et 
al. 2003a). Caution is always needed when strong CYP inhibitors (like ketoconazole) or 
inducers (like rifampicin) are co-administered with antihyperglycemic compounds 
metabolized by CYP enzymes (Scheen 2005). If the metabolism is inhibited, there is a 
risk for increased side effects, such as hypoglycemia. If the metabolism is induced, it 
can lead to lack of efficiency and the need for addition of another antihyperglycemic 
agent. A dose adjustment of the diabetes medicine might then be needed. 
 
Polymorphism is widely described in CYP2C8 and CYP2C9 enzymes, two very 
important enzymes also for antihyperglycemic agents (Scheen 2005). Polymorphism 
may influence the pharmacokinetics of glucose-lowering drugs and there is a risk of 
increased adverse effects or a lack of the antihyperglycemic effect. However, to date, 
the clinical relevance of polymorphism is unknown in patients with type 2 diabetes 
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mellitus and more research on the subject is needed. One major problem in the research 
of interactions of glucose-lowering drugs is that the studies are mainly performed only 
in healthy volunteers. The disease can, however, change the behavior of the compounds 
in the system and studies in subjects with type 2 diabetes mellitus are thus also needed. 
 
5.4.2 Interaction between angiotensin-converting enzyme inhibitors and 
sulphonylureas  
 
A significant interaction has been reported between the antihyperglycemic agents 
sulphonylureas and the antihypertensive agents angiotensin-converting enzyme (ACE) 
inhibitors (Arauz-Pacheco et al. 1990; Herings et al. 1995; Moore et al. 1997; Morris et 
al. 1997; Thamer et al. 1999). Together these compounds decrease blood glucose 
concentration more than sulphonylureas alone and might cause hypoglycemic episodes 
in patients with type 2 diabetes mellitus. The mechanism of the interaction is not 
known. It is thought that ACE inhibitors improve insulin sensitivity in the tissues (Chen 
et al. 1996). Increased hypoglycemic episodes can cause hospitalization and thus 
increased costs in the treatment of type 2 diabetes mellitus. According to Thamer et al. 
(1999) health care costs are 3 times higher in type 2 diabetes mellitus patients 
hospitalized for hypoglycemia compared with controls. Hospitalization for 
hypoglycemia in subjects using sulphonylureas and ACE inhibitors could be prevented 
with decent follow-up of these patients.  
 
The relationship between sulphonylureas and ACE inhibitors is controversial, however. 
Herings et al. (1995) claimed that as many as 14% of hospital admissions for 
hypoglycemia might be consequential to the use of ACE inhibitors. Other authors 
argued that the study design did not take into account of potential confounders such as 
renal function, heart failure or coexistent cardiovascular disease, factors that can 
predispose to hypoglycemia themselves (van Haeften 1995; Feher and Amiel 1995). 
Shorr and coworkers (1997) studied the interaction of sulphonylureas and ACE 
inhibitors in elders (mean age 787 years). They found no statistically significant 
difference in the occurrence of hypoglycemic episodes between subjects receiving the 
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test subjects or placebo. According to Shorr et al. the hypoglycemic interaction between 
sulphonylureas and ACE inhibitors is not present at least in elders. 
 
ACE inhibitors are reported to have cardio- and renoprotective features (Tashko and 
Gabbay 2010). For example in the HOPE (Heart Outcomes Prevention Evaluation) 
study (2000) ramipril lowered the risk of the myocardial infarction by 22%, stroke by 
33%, cardiovascular death by 37%, total mortality by 24%, revascularisation by 17% 
and overt nephropathy by 24%. Considering these beneficial effects of ACE inhibitors 
in addition to the insulin sensitivity increasing effect, ACE inhibitors are a very 
important part of the treatment of type 2 diabetes mellitus. ACE inhibitors are the 
primary treatment for hypertension in patients with type 2 diabetes mellitus also in 
Finland (Käypä hoito recommendation 2011). The hypoglycemic interaction between 
ACE inhibitors and sulphonylureas must be taken into account in the treatment of 
subjects with type 2 diabetes mellitus, but with decent monitoring these compounds can 
safely be used together. 
 
The mechanism of this significant interaction is not known. It has been thought to be 
caused by the ACE inhibitors ability to increase insulin sensitivity but the mechanism 
can as well be pharmacokinetic. The mechanism of this interaction will be studied in the 















II EXPERIMENTAL STUDY 
 
 
6 AIMS OF THE STUDY 
 
The aim of the experimental study was to study the hypoglycemic interaction of 
fosinopril and gliclazide in control rats and in a rat model of diabetes by studying the 
effects of fosinopril on the pharmacokinetics of gliclazide. Fosinopril and gliclazide 
have been documented to have an interaction, which leads to a greater decrease in blood 
glucose concentrations in human patients than gliclazide alone. The mechanism of this 
interaction is not known. In this study the mechanism of the interaction was studied and 
it was hypothesized to be pharmacokinetic. Also the effects of experimental diabetes on 
pharmacokinetics of gliclazide after single and repeated dosing were studied. To study 
the pharmacokinetics of the test items, approximately 700 plasma samples were 
collected after single and repeated per oral and/or intravenous administration. An 
HPLC-MS/MS method was developed for the measurement of the test item 
concentrations in the plasma samples and the pharmacokinetic parameters were 
determined. Plasma glucose concentrations were determined regularly during the study 
to explore the effects of the test items on blood glucose. Oral glucose tolerance (OGT) 
test was performed at baseline and in the end of the study. 
 
 




Goto-Kakizaki (GK) rat strain was used in the study because it embodies insulin 
intolerance and insulin resistance. A total of 18 adult male Goto-Kakizaki (GK) rats 
weighing circa 310 grams were obtained from Taconic, Denmark and 18 adult male 
Wistar (WI) rats weighing circa 340 grams were obtained from Harlan, Netherlands. 
GK male rats develop a condition resembling type 2 diabetes mellitus at approximately 
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14-16 weeks of age. The onset of diabetes was verified by measuring blood glucose 
levels.  
 
All procedures with animals were performed according to European Community 
Guidelines for the use of experimental animals (European Communities Council 
Directive 86/609/EEC) and the experimental setup was reviewed and approved by the 
Animal Care and Use Committee of the State Provincial Office of Southern Finland 
(APPENDIX 1). Animals were subjected to a constant daily cycle of 12 hours of light 
and 12 hours of darkness (06:00-18:00), constant temperature (21 ± 3 ºC) and relative 
humidity of 55 ± 15 %. Makrolon 3 cages (Bayer MaterialScience AG, Germany) were 
used and two animals were housed in each cage. Rats had access to commercial pelleted 
non-sterilised chow (RM1 E SQC, SDS England) and normal tap water ad libitum, 
except during fasting when access to food was restricted. Aspen chips (Tapvei Oy, 
Kaavi, Finland) were used as bedding. 
 
Animals were weighed once a week during the study and observed for clinical signs two 
times a day to ensure welfare. During weekends observations were done once a day. As 
it was described in the license for animal experiments, if the weight of an animal was 
reduced more than 10 % from the previous measuring or if the animal had any 
significant problems concerning welfare, it was euthanized (APPENDIX 1).  
 
Each rat was individually identified by tail numbering (1-36). Cages were respectively 
marked with cage cards indicating study number, animal numbers, group number, sex, 
strain, medication, dose of the item/items and the study period to avoid mixing. 
 
7.2 Study design 
 
Study was performed as described in  
Figure 1. A Protocol Outline was compiled (APPENDIX 2). Oral glucose tolerance 
(OGT) test was performed twice during the study, at the beginning and the end, and 
plasma glucose concentrations were determined weekly except when pharmacokinetic 
experiments were performed. Four separate pharmacokinetic experiments were 
performed during the study. Plasma samples were collected as described in Figure 2 
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after single and repeated per oral (p.o.) and intravenous (i.v.) administration of the test 
items in order to measure the concentrations of test items in plasma. After the single i.v. 
administration there was a wash-out period of one week before p.o. administration. 
 
plasma glucose, 
OGTT i.v. kinetics p.o. kinetics plasma glucose plasma glucose i.v. kinetics p.o. kinetics 
plasma glucose, 
OGTT 
week -2 week -1 week 1 week 2 week 3 week 4 week 5 week 6 
 
Figure 1. The study design. The time period when oral dosing was performed daily is 
marked in red. OGTT stands for oral glucose tolerance test. 
  
The control and diabetic animals were divided into three groups each (n=6). The first 
two subgroups were treated daily with 10 mg/kg/day gliclazide (Sigma-Aldrich, 
Germany), the second subgroups were treated with 10 mg/kg/day fosinopril (Euroasian 
Chemicals, Mumbai, India) and the third subgroups received a combination of 
gliclazide and fosinopril (Figure 2). Dosing was performed orally every day except on 
the days of intravenous pharmacokinetic experiments when all animals treated with 
gliclazide received their dose of 6 mg/kg intravenously. Test items were dissolved in a 
vehicle of 4.6% glycerine, 87.6% polyethylene glycol 400 and 7.8% distilled water for 
p.o. dosing and in a vehicle of NaOH in distilled water for i.v. dosing. For the 
preparation of the i.v. vehicle the same molar amount of NaOH and gliclazide was 
added. 




The time points for the pharmacokinetic studies, shown in Figure 2, were carefully 
selected to get a comprehensive picture of the pharmacokinetics of the test items in rats. 
For ten time points, the amount of blood withdrawn from each animal would have been 
too large. To avoid excess removal of blood, a sample was taken from each rat only 
every other time point. As a result, the number of studied rats is six in each group but 
only three in each time point. When the results were calculated, the results from two 
rats were united to form “complete” rats with ten time points. Each group formed 9 
“complete” rats when the results of all rats were combined with each other. If results 
were missing from some rats, the number of “complete” rats was smaller. In the results 
of pharmacokinetic experiments the number of studied individuals is therefore 6-9. 
 
7.3 Analytical procedures 
 
7.3.1 Analytical instrumentation and conditions  
 
Samples were analyzed using a modified method of Cui et al. (2007) (APPENDIX 3). 
The experiments were performed using Agilent HP 1100 liquid chromatograph 
(Hewlett-Packard GmbH, Waldbronn, Germany) and A PE Sciex API 3000 triple-
quadrupole mass spectrometer (Applied Biosystems/MDS Sciex, Canada). The column 
was an Atlantis
TM
 dC-18 (50 x 2.1 mm, 3 m particle size, Waters). The data were 
collected and processed with MDS Sciex Analyst 1.5 software.  
 
The LC method was slightly modified by using 15 mM ammonium acetate instead of 10 
mM and a linear gradient of 40-60% MeOH for 0-0.1 min, 60-90% MeOH for 0.1-3.5 
min and 90% MeOH for 3.5-5.5 min. The new method was validated modified 
according to the FDA guideline for validation of bioanalytical methods (FDA 2001). 
Method validation was carried out in terms of accuracy, precision, linearity, specificity, 






7.3.2 Sample preparation 
 
Blood samples (0.2 ml) were collected from the lateral tail vein of the rats as described 
in the study design (Figure 2). Samples were always taken from the opposite side of the 
tail than where the i.v. dose was given to avoid contaminations during sampling. Blood 
samples treated with the anticoagulant K2-EDTA were centrifuged (2870 g for 10 
minutes at 4 °C) to obtain plasma. After centrifugation, plasma samples were 
transferred into labeled plastic Eppendorf reaction tubes and stored at –20 ºC until 
analysis.  
 
The sample preparation method of Cui et al. (2007) was slightly modified using a 15-
minute shaker-extraction instead of a 3-minute vortex-extraction (APPENDIX 3). All 
the samples were made in duplicates for the analysis. Samples were prepared using 
diethyl ether-dichloromethane (3:1, v/v) liquid-liquid extraction. A mixture of methanol 
and ammonium acetate solution (4:6, v/v) was used to dissolve the analytes.  
 
A standard curve in triplicates was prepared approximately once a week at 
concentrations covering the expected concentration range in the plasma samples (5, 10, 
20, 35, 45 and 60 M for gliclazide and 0.4, 2, 4, 8, 14, 18 and 24 M for fosinoprilat). 
It was run separately or at intervals along with the test samples. Quality control (QC) 
samples in triplicates at three concentrations (3, 12 and 20 M for fosinoprilat and 7.5, 
30 and 50 M for gliclazide), also covering the expected concentration range, were 
prepared every day and analyzed with the samples to ensure the proper function of the 
system.  
 
Some of the samples needed to be diluted with blank plasma because there was not 
enough of the plasma sample left. The results of these samples were integrated normally 






7.4 Pharmacokinetic analysis 
 
Pharmacokinetic parameters for gliclazide were calculated by non-compartmental 
methods using the WinNonLin software package (version 5.2.1; Pharsight, Mountain 
View, California, USA). On the basis of the group plasma concentration–time data the 
area under the plasma concentration–time curve (AUC; in mg*h/L), the maximum 
plasma concentration of the drug (Cmax; in mg/L), the time to reach Cmax (Tmax; in h), the 
volume of distribution (V; in L), the clearance (CL; in L/h), the elimination rate 
constant determined as the negative slope of the terminal log-linear phase of the curve 
(kel; in h
-1
) and the mean residence time (MRT; in h) were determined. F is the oral 
bioavalilability of gliclazide and it was counted using Equation 1, where AUCp.o. and 
AUCi.v. are the area under the curves after per oral and intravenous dosing, and Dosep.o. 
and Dosei.v. the doses of per oral and intravenous dosing. The raw data for the 
pharmacokinetic analysis is in APPENDIX 4. 
 
F=(AUCp.o./AUCi.v.)*(Dosei.v./Dosep.o)   Equation 1 
 
7.5 Blood glucose concentration measurement and oral glucose tolerance test 
 
Blood glucose concentrations were measured from the lateral tail vein four times during 
the study after an overnight fast (14-18 h) using HemoCUE® Glucose 201+ analyzer. 
Blood glucose levels were considered as a marker for the effect of the medical 
treatments. Blood glucose levels were also used to determine the onset of diabetes in the 
GK rats.  
 
Oral glucose tolerance test was performed at baseline and at the end of the study. 
Animals received 2 g/kg D-glucose monohydrate (Sigma, Germany) before daily test 
item dosing after an overnight fast (14-18 h) by gavage. Blood glucose concentrations 
were determined using HemoCUE® Glucose 201+ analyzer at time points 0, 30, 60 and 
120 minutes. Because the concentrations in the samples of GK rats were above the 
working range of the device, all the blood samples of GK rats were diluted 1:1 (10 µl + 
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10 µl) using saline (0.9 %) before analysis. The samples of WI rats were analyzed 
without dilution to avoid too low values. 
 
Animals were divided into groups according to the results of the OGT test performed in 
the beginning of the study. GK rats formed three groups (I-III) and WI rats another 
three groups (IV-VI). Area under the curve (AUC) for the OGT test was calculated for 
each animal. Groups were formed to have similar average AUC to ensure similar ability 
to use glucose between groups. AUC of the blood glucose levels was determined using 
the trapezoidal method using Equation 2. 
 
AUC=[((Ca-C0)+(Cb-C0))/2] x t   Equation 2 
 
In Equation 2, C0 is the nominal blood glucose concentration, Ca and Cb are blood 
glucose concentrations at certain time points and t is the change of time between Ca 
and Cb. The nominal value of blood glucose was determined to be the zero point and the 
area was calculated above that and under the time-concentration curve.  
 
7.6 Statistical analysis 
 
Means and standard deviations were calculated using EXCEL® software (Microsoft 





8.1 Analytical procedures 
 
The main results concerning the analytical method used in this study are described 
shortly in this section. More detailed information can be found in APPENDIX 3. 
 
All the samples in this study were quantitatively analyzed for gliclazide and fosinoprilat 
using a modified validated version of the work of Cui et al. (2007) (APPENDIX 3). 
Fosinopril is a pro-drug and it is rapidly hydrolyzed into fosinoprilat both in the mucosa 
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of the gastrointestinal tract and the liver. Fosinoprilat was thus analyzed from the 
plasma samples in addition to gliclazide in this study. The analytical method was 
developed also to analyze fosinopril. It was suggested that there might be some 
differences between different groups in the amount of hydrolysis of fosinopril into 
fosinoprilat. Fosinopril could not, however, be detected reliably using the new method 
due to sensitivity problems.  
 
The method was successfully validated modified according to the FDA guideline for 
validation of bioanalytical methods (FDA 2001). The accuracy, precision, linearity, 
specificity, stability and reproducibility of the method were shown to comply with the 
requirements of FDA (Table 4, APPENDIX 3). The extraction recovery and matrix 
effect complied also with requirements. Accuracy and precision of the QC-samples 
were accepted when the Relative Standard Deviation (RSD%) did not exceed 15% 
(20% for low QC) and the accuracy was within 20% of the nominal value. There were 
some contamination problems in the analytical system for fosinoprilat but they 
diminished when a column wash of 0.1 % trifluoroacetic acid was added after every 
analytical batch.  
 
Table 4. The validation results of the analytical method. 
  Gliclazide Fosinoprilat 
Retention time (min) 3.2 3.8 
Linearity range (μM) 5-60 0.4-24 
r
2
 0.9905 - 0.9990 0.9934 - 0.9999 
Between-days repeatability (%RSD) 5.5% (8.3 μM) 6.1% (3.3 μM) 
 4.2% (30 μM) 8.1% (12 μM) 
 3.9% (50 μM) 3.8% (20 μM) 
 
The slope, the intercept and the correlation coefficient were determined from every 
standard curve. On the basis of acceptable accuracy and good correlation coefficients 
(≥0.9905), the relationship between area ratio and concentrations was linear within the 
studied concentration range (Table 4). The limit of quantification (LOQ, signal-to-noise 
ratio S/N of at least 10) was determined for all analytes. In the cases where 
contamination was observed in the blank samples, LOQs were determined with a 
concentration that produced a S/N ratio ten times higher than the peak of the blank 
  
43 
sample. The LOQ for gliclazide in plasma was 1 μM and the LOQ for fosinoprilat 
varied from 0.4 μM to 14 μM depending on the amount of contamination.  
 
The highest concentration in the plasma samples for gliclazide was approximately 260 
µM and 13 µM for fosinoprilat. The concentration of fosinoprilat in the plasma samples 
was very small and this caused sensitivity issues. The contamination of fosinoprilat in 
the analytical system was also remarkable. The aim of the study, however, was to study 
the effect of fosinopril on the pharmacokinetics of gliclazide and thus only the plasma 
concentrations of gliclazide are presented. 
 
8.2 Blood glucose concentration measurement 
 
Blood glucose concentrations were determined from all rats four times during the study 
to determine the effect of the medical treatments on the blood glucose levels. Rats were 
fasted approximately 14 hours before the experiment. Blood glucose levels were 
significantly higher in all the diabetic groups compared to the control groups (Figure 3).  
 
 
Figure 3. The results of the blood glucose measurement in the beginning and the end of 
the study in all groups. Blood glucose concentrations decreased during the study in all 
the groups except in the WI group receiving fosinopril alone (n=3-6, mean  SD, 








































8.2.1 Control rat 
 
The progression of the blood glucose concentrations in control rats during the study was 
variable (Figure 4). In the combination treatment group, blood glucose levels were 
lower than in the other two groups already in the beginning of the study. The blood 
glucose first increased slightly but then decreased. In the fosinopril group, blood 
glucose stayed similar during the entire study. A contradictory result was found in the 
control rats receiving gliclazide alone because the blood glucose concentration first 
decreased but then increased towards the end of the study. The difference in the results 
between the baseline and the end of the study was most remarkable in the gliclazide 
group (-4.5%) and slightly smaller in the combination treatment group (-2.0%) (Table 
5). The blood glucose concentration in the fosinopril group increased 2.5% during the 
study. The concomitant administration of fosinopril and gliclazide in control rats had a 
lowering effect on the blood glucose concentrations during the study. Gliclazide alone, 
however, had a more significant effect.  
 
 
Figure 4. The progress of blood glucose concentrations during the study in Wistar rats 
(n=5-6, mean ± SD). 
 
8.2.2 Rat model of diabetes 
 
The progression of the blood glucose concentrations in Goto-Kakizaki rats during the 




































lower than in the other two groups in the beginning of the study and they increased until 
the second week of the study. This might be a sign that not all the rats had developed 
diabetes by the beginning of the study. Blood glucose levels in the combination group 
decreased after two weeks but stayed similar for the rest of the study. Glucose levels of 
gliclazide group decreased until the week three but increased after that ending up to be 
similar than in the fosinopril group. Blood glucose in the fosinopril group first 
decreased and then increased but decreased again.  
 
 
Figure 5. The progress of blood glucose concentrations during the study in Goto-
Kakizaki rats (n=3-5, mean ± SD). 
 
Table 5. The percent of change in the blood glucose concentrations (mmol/L) during the 
study (n=3-6, mean ± SD, G=gliclazide, F=fosinopril, G+F=gliclazide+fosinopril). 
Treatment Week 0   Week 6   % of change 
  Mean ± SD Mean ± SD   
Rat model 
of diabetes           
G 8.9 0.79 8.3 0.86 -5.8 % 
F 8.8 0.70 8.3 0.94 -5.8 % 
G+F 8.0 0.86 7.3 0.12 -8.5 % 
            
Control rat           
G 6.0 0.31 5.7 0.53 -4.5 % 
F 6.0 0.65 6.2 0.91 2.5 % 







































In GK rats, gliclazide alone caused a similar decrease of 5.8% in the blood glucose 
concentration between the beginning and the end of the study than fosinopril (Table 5). 
A more significant decrease of 8.5% was seen when fosinopril and gliclazide were 
administered together. In conclusion, the concomitant administration of gliclazide and 
fosinopril might have a stronger effect on the blood glucose concentration in the GK 
rats than gliclazide treatment alone. Three animals of the combination group were lost 
during the study, but due to reasons unrelated to the test items.  
 
8.3 Oral glucose tolerance test 
 
Oral glucose tolerance test was performed at the baseline and at the end of the study. 
Rats were grouped for the study according to the AUC of the first OGT test to get 
groups, which have a similar usage of glucose (Figure 6). As seen from the deviation of 
the figure, the differences between different WI groups and different GK groups were 
very small. Similar ability to use glucose between the groups was important for the 
comparison of the results in the study. Rats were fasted (14-18 h) before the experiment. 
The length of the fast was different between GK rats numbered 1-9 than 10-18 and WI 
rats numbered 19-27 than 28-36. The length of the fast had, however, no significant 
effect on the results of OGT test.  
 
 
Figure 6. The results of the rat model of diabetes and control rats of the first OGT test. 
The deviation is the standard deviation between the groups (n=6, mean ± SD, 






































There was a significant difference in the AUC of control rats and rat model of diabetes 
in the beginning of the study (Figure 7). Control rats had lower nominal blood glucose 
levels than GK rats, and when glucose was administered, the blood glucose rose 
controlled but returned close to the nominal value by the end of the experiment (Figure 
6). The insulin response to glucose in GK rats is deranged and thus GK rats produced a 
stronger effect on glucose. Glucose levels reached high quickly and did not return back 
to the nominal values in two hours.  
 
 
Figure 7. The AUC of OGT test results in the beginning and the end of the experiment 
in different groups. A more significant decrease was only seen in the diabetic group 
receiving combination treatment (n=3-6, mean ± SD, GK=Goto-Kakizaki rat, 
WI=Wistar rat, G=gliclazide, F=fosinopril, G+F=gliclazide+fosinopril). 
 
8.3.1 Control rats 
 
There was no decrease in the AUC between the beginning and the end of the study in 
any group in control rats (Figure 7). On the contrary, the AUC in all the groups 









































Table 6. The AUC (h*mmol/L) of the OGT tests compared at baseline and at the end of 
the study (n=3-6, mean ± SD, G=gliclazide, F=fosinopril, G+F=gliclazide+fosinopril). 
Treatment Week 0   Week 6   % of change 
  Mean ± SD Mean ± SD   
Rat model 
of diabetes           
G 25.3 2.20 27.0 3.22 6.66% 
F 25.6 2.43 23.4 2.82 -8.62% 
G+F 25.7 4.77 18.6 9.27 -27.6% 
           
Control rat          
G 3.54 1.02 3.69 1.33 4.31% 
F 3.60 1.05 3.89 1.42 7.86% 
G+F 3.63 0.93 4.21 0.79 16.0% 
 
8.3.2 Animal model of diabetes 
 
Figure 8. The results of the OGT test for GK groups receiving gliclazide or combination 
treatment in the beginning (week 0) compared to combination treatment at the end 
(week 6). There was a significant difference between the results but the standard 
deviation seems to fade it out a bit. The combination treatment lowered the AUC more 










































GK rats had big differences between the results of the first and the second OGT test 
(Figure 7). Gliclazide and fosinopril separately had only a minor effect on the AUC of 
OGT test in GK rats but the combination treatment decreased the AUC for 27.6% 
(Table 6). The deviation in the combination group was, however, also more significant 
compared to the other two groups. The AUC in the fosinopril group decreased 8.6% and 
the AUC in the gliclazide group increased 6.7%. At the end of the study, the AUC of 
the group receiving combination medication was smaller than the AUC of the group 
receiving gliclazide alone (Figure 8).  
 
8.4 The pharmacokinetic interaction between gliclazide and fosinopril 
 
The hypothesis of this work was that the mechanism of the hypoglycemic interaction 
between gliclazide and fosinopril is pharmacokinetic. Pharmacokinetic experiments 
were performed after intravenous and per oral administration of the test items in the 
beginning and the end of the study. A wash-out period of one week was held in the 
beginning of the study between oral and intravenous experiments. A few of the 
intravenous dosings failed and part of the test item was administered into the tissue. 
This could be seen as an absorption phase in the time-concentration curve. These 
samples were excluded. 
 
Table 7. The pharmacokinetic parameters and the percent of difference after gliclazide 
or gliclazide + fosinopril administration in the rat model of diabetes (n=6, mean  SD). 
    gliclazide SD gliclazide + fosinopril SD % of change 
i.v. (6 mg/kg)      
CL L/h 0.015 0.00 0.013 0.00 -9.38 % 
V L 0.060 0.01 0.055 0.01 -8.10 % 
AUC h*mg/L 130 8.80 134 10.3 2.85 % 
kel h
-1
 0.24 0.01 0.24 0.04 -0.15 % 
       
p.o. (10 mg/kg)      
tmax h 5.00 1.10 6.00 0.00 20.0 % 
Cmax mg/L 19.5 2.69 21.1 0.08 8.57 % 
AUC h*mg/L 208 78.2 180 36.0 -13.4 % 
kel, app h
-1
 0.16 0.08 0.15 0.04 -6.77 % 
MRT h 6.30 1.22 5.96 1.08 -5.47 % 
F  0.95 0.31 0.81 0.17 -14.3 % 
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The hypoglycemic interaction of gliclazide and fosinopril was not seen in the control 
rats. Interaction was only visible in the rat model of diabetes after the oral glucose 
tolerance test and the blood glucose concentration measurements. Therefore, only the 
results of the GK rats will be reported here. The results of GK rats after a single dose 
and after multiple doses of gliclazide alone or gliclazide and fosinopril together were 
similar. Therefore only the results after repeated dosing will be reported here.  
 
 
Figure 9. Plasma concentration-time profiles after i.v. administration of gliclazide alone 
and with fosinopril in the rat model of diabetes (n=1-3, med  min-max). 
 
The concentration–time profiles for gliclazide alone and for gliclazide with fosinopril 
after i.v. and p.o. administration in rat model of diabetes were similar (Figure 9 and 
Figure 10). The mean pharmacokinetic (PK) parameters of gliclazide alone and with 
fosinopril are shown in Table 7. There was no significant unequivocal difference in the 
pharmacokinetics of gliclazide between the administration of gliclazide alone and the 
administration with fosinopril either after i.v. or p.o. dosing. After i.v. dosing CL and V 
were 9.38% and 8.10% smaller for gliclazide with fosinopril (0.013 L/h; 0.055 L) than 
for gliclazide alone (0.015 L/h; 0.060 L). AUC was 2.85 % greater and kel only 0.15 % 
smaller after combination treatment (134 h*mg/L; 0.24 h
-1
) compared to gliclazide 








































Figure 10. Plasma concentration-time profiles after p.o. administration of gliclazide 
alone and with fosinopril in the rat model of diabetes (n=1-3, med  min-max). 
 
After p.o. dosing tmax was 20.0 % greater for gliclazide with fosinopril (6.00 h) than for 
gliclazide alone (5.00 h), but AUC was 13.4% smaller for gliclazide with fosinopril 
(180 h*mg/L) than for gliclazide alone (208 h*mg/L) (Table 7). MRT was 5.47% and F 
14.3% smaller after combination treatment (5.96 h; 0.81) than after gliclazide treatment 
(6.30 h; 0.95). After p.o. administration of gliclazide with fosinopril, Cmax was 8.57% 
greater and kel, app 6.77% smaller than after administration of gliclazide alone. Under the 
circumstances, the interaction between gliclazide and fosinopril seemed not to be 
pharmacokinetic.  
 
8.5 Pharmacokinetics of gliclazide in control rat and rat model of diabetes 
 
The concentration–time profiles for gliclazide after p.o. and i.v. administration in 
control rats and in rat model of diabetes are shown in Figure 11 and Figure 12. The 
profile was similar in WI and GK rats but bigger in GK rats. The mean pharmacokinetic 
parameters are shown in  
 
Table 8. Results of the control and diabetic groups receiving gliclazide alone after 
repeated dosing will be discussed in more detail here. Results of the groups receiving 


































receiving gliclazide after single dosing were all similar and comparable with the results 
shown here. 
 
Table 8. The pharmacokinetic parameters and the percent of difference of gliclazide in 
control rats and in rat model of diabetes (n=6-9, mean  SD). 
    control rat SD rat model of diabetes SD % of change 
i.v. (6 mg/kg)      
CL L/h 0.024 0.01 0.015 0.00 -40.7 % 
V L 0.065 0.02 0.060 0.01 -6.85 % 
AUC h*mg/L 102 30.1 130 8.80 27.3 % 
kel h
-1 
0.39 0.09 0.24 0.01 -37.7 % 
       
p.o. (10 mg/kg)      
tmax h 2.67 1.94 5.00 1.10 87.5 % 
Cmax mg/L 20.6 1.49 19.5 2.69 -5.68 % 
AUC h*mg/L 131 13.3 208 78.2 58.9 % 
kel, app h
-1
 0.15 0.04 0.16 0.08 6.59 % 
MRT h 4.47 0.28 6.30 1.22 41.0 % 
F  0.81 0.17 0.95 0.31 17.2 % 
 
 
Figure 11. Plasma concentration-time profiles of gliclazide after i.v. administration in 
control rats and in rat model of diabetes (n=1-3, med  min-max). 
 
After i.v. administration, the CL of gliclazide was 40.7% smaller in the rat model of 







































Table 8). Volume of distribution was similar in the rat model of diabetes (0.060 L) and 
in the control rats (0.065 L) with the percent of difference of 6.85%. In accordance with 
CL, AUC was 27.3 % greater in the rat model of diabetes (130 h*mg/L) than in control 
rats (102 h*mg/L). The elimination rate constant was also smaller in the rat model of 
diabetes (0.24 h
-1
) compared to normal rats (0.39 h
-1
). In conclusion, the elimination of 




Figure 12. Plasma concentration-time profiles of gliclazide after p.o. administration in 
control rats and in the rat model of diabetes (n=1-3, med  min-max). 
 
After p.o. administration gliclazide absorbed slower in the rat model of diabetes than in 
control rats and tmax was different being 2.67 hours for control rats and 5.00 hours for 
the rat model of diabetes (percent of difference 87.5%) ( 
Table 8). Cmax was similar, 20.6 mg/L for control rats and 19.5 mg/L for the rat model 
of diabetes, with percent of difference of 5.68%. AUC and MRT were bigger for the rat 
model of diabetes (208 h*mg/L; 6.30 h) than for control rats (131 h*mg/L; 4.47 h) with 
percent of difference of 58.9% and 41.0%, and the oral bioavailability was better for the 
rat model of diabetes (0.95) than for the control rats (0.81). The apparent elimination 
rate constant of gliclazide was somewhat greater in the rat model of diabetes than in the 
control rats with kel, app 6.59% bigger in the rat model of diabetes (0.16 h
-1
) than in 
control (0.15 h
-1


































diabetes seemed to be slower and the bioavailability better than in the control rats after 
per oral administration.  
 
8.6 Pharmacokinetics of gliclazide after single and repeated dosing 
 
The concentration–time profile for gliclazide after single and repeated p.o. and i.v. 
administration in the rat model of diabetes are shown in Figure 13 and Figure 14. The 
mean PK parameters are shown in Table 9. Results of the rat model of diabetes 
receiving gliclazide alone are shown here. Similar results were also seen in control rats 
receiving combination treatment or gliclazide alone, and in the rat model of diabetes 
receiving combination treatment. 
 
Table 9. The pharmacokinetic parameters and the percent of change after single and 
repeated dosing of gliclazide in the rat model of diabetes (n=6-9, mean  SD). 
    single dosing SD repeated dosing SD % of change 
i.v. (6 mg/kg)      
CL L/h 0.014 0.00 0.015 0.00 2.42 % 
V L 0.063 0.01 0.060 0.01 -5.02 % 
AUC h*mg/L 116 14.7 130 8.80 12.5 % 
kel h
-1
 0.23 0.03 0.24 0.01 6.93 % 
       
p.o. (10 mg/kg)      
tmax h 4.67 1.00 5.00 1.10 7.14 % 
Cmax mg/L 16.7 4.09 19.5 2.69 16.8 % 
AUC h*mg/L 106 17.5 208 78.2 96.1 % 
kel, app h
-1
 0.12 0.02 0.16 0.08 35.7 % 
MRT h 5.18 0.18 6.30 1.22 21.6 % 
F  0.58 0.14 0.95 0.31 63.9 % 
 
After both single and repeated i.v. administration of gliclazide, the concentration-time 
profile was similar (Figure 13 and Figure 14). The concentration-time curve was, 
however, little bigger after repeated dosing, especially after repeated p.o. dosing. After 
i.v. dosing, the clearance was similar, only 2.42% bigger after repeated (0.015 L/h) 
compared to single (0.014 L/h) dosing (Table 9). Volume of distribution was also 
similar after single dosing (0.063 L) and repeated dosing (0.060 L). Elimination rate 
constant of gliclazide was bigger after repeated (0.24 h
-1





dose with percent of change of 6.93%. The biggest difference in the pharmacokinetics 
of gliclazide after single and repeated i.v. dosing was seen in the value of AUC. AUC 
was greater, 130 h*mg/L, after repeated dosing compared to 116 h*mg/L after a single 
dose, with the percent of change of 12.5%. In conclusion, pharmacokinetics after a 
single intravenous dose of gliclazide was somewhat similar than after repeated dosing. 
 
 
Figure 13. I.v. plasma concentration-time profiles after single and repeated dosing of 
gliclazide in the rat model of diabetes (n=1-3, med  min-max). 
 
Tmax was similar after repeated per oral dosing (5.00 h) and after a single per oral dose 
(4.67 h) of gliclazide with percent of change of 7.14% in the rat model of diabetes 
(Table 9). AUC and Cmax were different after single and repeated dosing. Oral 
bioavailability was also better after repeated dosing (0.95) than after a single dose 
(0.58). Cmax and AUC were 16.8% and 96.1% greater after repeated (19.5 mg/L; 208 
h*mg/L) than after single (16.7 mg/L; 106 h*mg/L) dosing. Elimination rate constant of 
gliclazide was also different after repeated dosing compared to a single dose with kel 
35.7% greater after repeated (0.16 h
-1
) dosing than after a single (0.12 h
-1
) dose. MRT 
was greater after repeated dosing (6.30 h) compared to single dosing (5.18 h) with 
percent of change of 21.6%, respectively. In conclusion, pharmacokinetics of gliclazide 
in the rat model of diabetes after a single per oral dose of gliclazide seemed to be 






































Figure 14. P.o. plasma concentration-time profiles after single and repeated dosing of 





The aim of the experimental research was to study the hypoglycemic interaction of 
fosinopril and gliclazide in control rats and in a rat model of diabetes by studying the 
effects of fosinopril on the pharmacokinetics of gliclazide. ACE inhibitors and 
sulphonylureas have been documented to have an interaction, which produces a greater 
decrease in blood glucose concentrations in human patients than a sulphonylurea alone 
(Arauz-Pacheco et al. 1990; Herings et al. 1995; Moore et al. 1997; Morris et al. 1997; 
Thamer et al. 1999). The mechanism of this interaction is not known. In this study the 
mechanism of the interaction was studied and it was hypothesized to be 
pharmacokinetic. Also the effects of experimental diabetes on pharmacokinetics of 
gliclazide after single and repeated dosing were studied. To study the pharmacokinetics 
of the test items, approximately 700 plasma samples were collected after single and 
repeated per oral and/or intravenous administration. A HPLC-MS/MS method was 
developed for the measurement of the test item concentrations in the plasma samples, 
and the pharmacokinetic parameters were determined. Plasma glucose concentrations 


































blood glucose. Oral glucose tolerance test was performed at baseline and in the end of 
the study. 
 
There were a lot of problems, which were solved during the analysis of the test items. 
The analytical procedure of Cui et al. (2007), which was validated for fosinopril, was 
developed further to also cover gliclazide. The concentrations for fosinoprilat were very 
low, the peak shapes were poor at times and the contamination in the analytical system 
was remarkable. To improve these, the buffer concentration was changed, the pH was 
changed and washes were added between the samples and the batches. The injection 
volume had to also be changed when the concentrations of gliclazide were too high. The 
conditions were optimized, however, and a validated HPLC-MS/MS method was 
developed. Some samples could not be analyzed due to human errors and some had to 
be excluded, which diminished the number of parallel samples.  
 
Some problems also occurred during the administration of the test substances to the test 
animals. Some samples had to be excluded because administration had failed, and some 
rats had to be eliminated due to errors in administration. A few animals also died due to 
reasons not related to the study. These factors also diminished the number of parallel 
samples. The number of parallel samples was only three in some cases and this 
deteriorates the reliability of the results. More research is therefore needed to verify the 
results of this sudy. 
 
The test items for the study were chosen on the basis of the work of El-Batran and 
coworkers (2004). Gliclazide and fosinopril were shown to decrease blood glucose 
concentration in rats more when administered concurrently than when gliclazide was 
administered alone. Rats were given 10 mg/kg of gliclazide and/or fosinopril orally in 
this study. The doses were chosen on the basis of literature. Dachicourt and coworkers 
(1998) reported that the dose of 10 mg/kg of gliclazide produces plasma levels of 
gliclazide similar to those seen in humans. They also reported that this dose results in an 
increase in insulin secretion in control rats and in a rat model of diabetes similar to that 
seen in humans. Grove and coworkers (1995) wrote that the dose of 10 mg/kg of 
fosinopril is scaled to match a human clinical treatment dose of 1 mg/kg/day.  
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Gliclazide has been reported to have variable effects on plasma and blood glucose 
concentration in rats. Dachicourt et al. (1998) for example studied the effect of 
gliclazide (10 mg/kg/day) in Wistar and Goto Kakizaki rats for four weeks, and reported 
plasma glucose levels of 10.7 mmol/L for untreated GK rats, 8.1 mmol/L for treated GK 
rats and 6.6 mmol/L for untreated WI rats at the end of the experiment. Dachicourt and 
coworkers measured plasma glucose concentration instead of blood glucose, and plasma 
glucose levels are 10-15 % higher than blood glucose concentrations. In the work of 
Louro et al. (2011), GK rats receiving a high cholesterol diet were administered 10 
mg/kg/day of gliclazide in drinking water for one month. At the end of the study, their 
blood glucose levels were 7.8 mmol/L for untreated and 5.5 mmol/L for treated rats. 
Sena et al. (2009) administered 10 mg/kg/day gliclazide for four weeks for GK rats fed 
on a high-fat diet. Blood glucose concentrations were also 7.8 mmol/L for untreated rats 
and 5.5 mmol/L for treated rats. These results are in accordance, and in all of these 
studies gliclazide affected the glucose concentration remarkably. The results show that 
gliclazide can be used to study the effects of gliclazide in Goto-Kakizaki rats. In the 
current study, blood glucose concentrations were 8.3 mmol/L for the control GK rats 
(=fosinopril group), 8.3 mmol/L for gliclazide treated GK rats, 6.2 mmol/L for control 
WI rats (=fosinopril group) and 5.7 mmol/L for gliclazide treated WI rats after six 
weeks of gliclazide or fosinopril administration. In control, but not in the rat model of 
diabetes, there is a small difference between treated and untreated individuals. Either 
gliclazide does not lower the blood glucose concentration in GK rats compared to 
controls, or fosinopril also lowers the blood glucose concentration. There are studies 
indicating that ACE inhibitors would have an effect on blood glucose concentrations but 
the impact is not clear (Murad et al. 2009). Compared to the results of the other studies, 
gliclazide had virtually no effect on the blood glucose concentrations in this study. Also 
the difference in blood glucose concentrations in different groups between the 
beginning and the end in this study was minor. One reason may be that diabetes had not 
broken out in the studied rats in the beginning of the study. Another explanation could 
be that the daily gliclazide administration was performed after the measurement of 
blood glucose concentration. A stronger effect might have been seen if gliclazide was 
administered a certain period of time before the experiment on the days of the blood 
glucose concentration measurements. Gliclazide is known to increase -cell insulin 
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stores and increase the glucose-induced insulin release in the adult GK rats (Dachicourt 
et al. 1998). It would have been easy and informative also to measure insulin levels 
during the study.  
 
El-Batran et al. (2004) used a similar study design as was used in this study. They 
administered gliclazide (7.2 mg/kg) and fosinopril (0.9 mg/kg) separately and 
concurrently to control (Sprague-Dawley) rats and alloxan-induced rat model of 
diabetes for 30 days and performed serum glucose measurements every two weeks. All 
drugs showed an effect on serum glucose levels. Gliclazide decreased glucose levels 
from 5.4 mmol/L to 4.1 mmol/L in control rats and from 11.8 mmol/L to 8.8 mmol/L in 
the rat model of diabetes during the study. Fosinopril decreased glucose levels less, 
from 5.3 mmol to 4.7 mmol/L in control and from 11.6 mmol/L to 10.0 mmol/L in the 
rat model of diabetes. Gliclazide and fosinopril administered together had the greatest 
impact on the serum glucose concentrations during the study. Concurrent administration 
decreased glucose levels from 5.6 mmol/L to 4.1 mmol/L in control and from 11.3 
mmol/L to 8.2 mmol/L in the rat model of diabetes. The decreases in percentages vary 
from 12% for fosinopril to 38% for concurrent gliclazide and fosinopril administration. 
Serum glucose levels are about 15% higher than blood glucose levels. 
 
In the current study, blood glucose concentrations were determined weekly from all rats 
except when pharmacokinetic experiments were performed. Blood glucose 
concentrations in the rat model of diabetes (7.3-8.9 mmol/L) were higher in all groups 
compared to control rats (5.4-6.2 mmol/L) during the entire experiment. The 
administration of gliclazide, fosinopril or gliclazide and fosinopril concurrently had no 
significant effect on the blood glucose concentration in control rats. In the rat model of 
diabetes, however, gliclazide and fosinopril had a similar small effect on the blood 
glucose concentrations and gliclazide and fosinopril administered together produced a 
bigger effect. The percents of change in the study of el-Batran et al. (2004) were, 
however, considerably greater than in the current study. In this study the percentages 
vary from a 2.5% increase for fosinopril to an 8.5% decrease for combination 
medication. According to the results of this study, gliclazide and fosinopril might have 
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an additive effect on blood glucose concentration in Goto Kakizaki rats when 
administered simultaneously, but the effect is rather feeble. 
 
Someya et al. (2009) administered 10 mg/kg gliclazide to Zucker fatty rats for two 
weeks and performed an OGT test after the first and the last dose. Gliclazide had a more 
significant effect on the AUC of the OGT test after the first dose of gliclazide, but had 
no effect after the last dose. This, in their opinion, is due to secondary failure. 
Secondary failure is a state known to occur in some patients after a period of time using 
sulphonylureas. For an unknown reason, the effect of sulphonylureas on blood glucose 
levels weakens. Also in the current study gliclazide first caused a decrease in the blood 
glucose levels in most groups but in many groups the levels increased again toward the 
end of the study. This could be explained by the secondary failure. The study of 
Someya et al. (2009) on Zucker fatty rats lasted for two weeks but secondary failure in 
humans occurs after years of sulphonylurea use. 
 
In the previous studies, administration of gliclazide has virtually had no effect on the 
outcome of OGT test in GK rats. Sena with coworkers (2009) and Louro with 
coworkers (2011) reported that the 2-hour glucose concentration value after a glucose 
load was actually higher in gliclazide treated (17.6 mmol/L; 19.0 mmol/L) than in non-
treated rats (16.8 mmol/L; 16.8 mmol/L). Dachicourt and coworkers (1998) reported a 
marginally lower incremental plasma glucose area for gliclazide treated rats (20.8 
min*mmol/L) than for non-treated rats (21.4 min*mmol/L). These results are in 
agreement with the results of this study. In this study, the administration of gliclazide 
alone had no effect on the AUC of OGT test in the rat model of diabetes and in control 
rats. In control rats, the administration of fosinopril or gliclazide and fosinopril 
concurrently had no significant effect either. In the rat model of diabetes, however, the 
administration of gliclazide and fosinopril concurrently lowered the AUC of OGT test. 
In accordance with the results of plasma blood glucose concentration measurement, 
gliclazide and fosinopril seem to have an additive effect on the AUC of OGT test. Also 
fosinopril alone had a minor effect. The oral glucose tolerance test was performed in the 
beginning and at the end of the study. The AUC of OGT test was significantly greater 
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for the rat model of diabetes (18.6-27.0 h*mmol/L) than for control rats (3.54-4.21 
h*mmol/L).  
 
Pharmacokinetics of gliclazide has been reported to differ between control rats and rat 
models of diabetes in several studies (Stetinová et al. 2007; Al-Salami et al. 2008; 
Mikov et al. 2008; Talari et al. 2010). Al-Salami with coworkers and Mikov with 
coworkers administered 20 mg/kg gliclazide to control Wistar rats and compared them 
with alloxan-induced (30 mg/kg) rat model of diabetes. They reported greater gliclazide 
plasma concentrations for control than for the rat model of diabetes. Stetinová and 
coworkers (2007) administered 25 mg/kg gliclazide to control Wistar rats and to 
alloxan-induced (50 mg/kg) rat model of diabetes. They found slightly higher gliclazide 
concentration in the rat model of diabetes than in control rats. Talari and coworkers 
(2010) induced diabetes to Wistar rats using an intraperitoneal injection of 
streptozotocin (45 mg/kg) and compared them to control Wistar rats. After 
administration of 40 mg/kg of gliclazide, they reported similar pharmacokinetic 
parameters for control rats and for rat model of diabetes. These results partly agree with 
the results seen in this study. A difference was found in all groups in the 
pharmacokinetics of gliclazide when control rats and the rat model of diabetes were 
compared. Plasma concentrations of gliclazide were higher in the rat model of diabetes 
and pharmacokinetic parameters were greater for them. The pharmacokinetics of 
gliclazide was slower in the rat model of diabetes, especially when measured at the end 
of the study. These results indicate that it is important to study drugs also on animal 
models and not only in normal animals.  
 
In the current study, no significant difference was seen in the pharmacokinetics of 
control rats and the rat model of diabetes when they were compared after the 
administration of gliclazide and fosinopril concurrently or gliclazide alone. The 
hypoglycemic interaction, which can be seen in GK rats after blood glucose 
concentration measurement and OGT test, is thus probably not pharmacokinetic. A 
difference was also seen in the pharmacokinetics of gliclazide after single compared to 
repeated dosing. The pharmacokinetics of gliclazide is slower after repeated than after 
single dosing. A similar change was seen in all the groups receiving gliclazide. 
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Although several papers have been written concerning the hypoglycemic interaction of 
sulphonylureas and ACE inhibitors, including this study, it still remains unclear, what is 
the mechanism of the interaction and the actual significance and severity of it. Also the 
influences of ACE inhibitors on glucose metabolism are still contradictory. The results 
of this study refer, that there is a non-pharmacokinetic interaction and that ACE 
inhibitors do have an effect on glucose metabolism. In the future, the interaction and the 
effects of ACE inhibitors should be studied systematically using different 
sulphonylureas and ACE inhibitors under a similar study design. It is possible that the 
effects are greater in certain ACE inhibitors and sulphonylureas than others.  
 
There are more than 200 million people with type 2 diabetes mellitus in the world, and a 
great percentage of them use sulphonylureas as medication, though new, more effective 
drugs conquer the markets. People with type 2 diabetes mellitus are in a greater risk for 
kidney and cardiovascular diseases and they are thus also on medication for for example 
cholesterol and hypertension. This polypharmacy is a serious risk for drug-drug 
interactions, which can lead to unnecessary use of drugs, expensive hospitalizations or 
even death. For example sulphonylureas and ACE inhibitors have been reported to 
cause hypoglycemic episodes in patients with type 2 diabetes mellitus when used 
concurrently. This was also shown in the current study. On a daily basis, hypoglycemia 
is mostly an unpleasant disorder for patients with type 2 diabetes mellitus but it can 
even be life threatening. To prevent the unease caused to the patients and the extra costs 
to the society, it is very important to study drug interactions and to understand their 
mechanism. It is also very important to study drug interactions in animal models and 
not only in control rats because many diseases are known to affect the behavior of the 
drugs in the system. 
 
 
10 CONCLUSIONS  
 
Gliclazide, a sulphonylurea, lowers blood glucose levels in Goto Kakizaki rats more 
when administered with fosinopril, an ACE inhibitor, than when administered alone. 
This is shown in the results of blood glucose concentration measurement and OGT test. 
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On the basis of the pharmacokinetic studies performed in this study, the mechanism of 
the interaction seems not to be pharmacokinetic. It might be additive pharmacodynamic. 
Based on the results of this study, the pharmacokinetics of gliclazide seems to be slower 
in the rat model of diabetes than in the control rats. The pharmacokinetics of gliclazide 
also seems to change over time when it is repeatedly administered per orally. More 
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rauteen liittyy vakavia ja invalidisoivia liitännäissairauksia, ja hoitamatto- 
mana sairaus johtaa kuolemaan. Sairauteen on onnistuttu kehittämään 
useita tehokkaita lääkeaineita, mutta nykyiset lääkkeet eivät estä vaan 
ainoastaan hidastavat taudin etenemistä sekä lisäsairauksien puhkeamis-
ta. Diabetes yksinään johtaa harvoin ihmisen kuolemaan, mutta siihen 
liittyvät lisäsairaudet (liitännäissairaudet) kyllä. Tästä syystä diabeetikko 
joutuu syömään diabeteksen hoitoon tarkoitetun lääkkeen lisäksi paljon 
muita lääkkeitä. Lääkkeiden kinetiikka saattaa myös muuttua diabeteksen 
etenemisen myötä liitännäissairauksien vuoksi. 
 
Tyypillisesti uusia lääkeaineita tutkitaan prekliinisissä kinetiikkakokeissa 
ainoastaan terveillä eläimillä. Patologisessa tautitilassa lääkeaineiden far-
makokinetiikka saattaa kuitenkin muuttua ja vaikuttaa esimerkiksi syntyviin 
metaboliitteihin sekä yhteisvaikutuksiin samanaikaisesti annosteltujen lää-
keaineiden välillä. Siksi taudin vaikutusta lääkeaineiden farmakokinetiik-
kaan olisi myös tärkeää tutkia. Tässä tutkimuksessa käytettävällä mallilla 
on mahdollista tutkia lääkeaineen farmakokinetiikkaa, diabeteksen vaiku-
tuksia tutkittavan aineen farmakokinetiikkaan sekä samanaikaisesti annos-
teltujen lääkeaineiden välisiä interaktioita. 
 
Eläimille tehtävät toimenpiteet: Eläimille kehittyy hoitamattomana diabetes 
itsekseen. Ensimmäisessä mallissa testiaineen ja diabeteslääkkeen päivit- 
täiset annostelut ennen taudin puhkeamista enimmillään 60 vrk ajan. An- 
nostelureitteinä injisointi laskimoon, vatsaonteloon tai nahan alle, tai anto 
suun kautta. Toisessa mallissa diabeteksen annetaan kehittyä pidemmälle 
ja hoito aloitetaan 1-2 viikon kuluessa sokeriarvojen noususta. 
 
Verinäytteiden keräys häntälaskimosta eri aikapisteissä tai sydänpunktiolla 
terminaalianestesiassa. Tutkimukseen voidaan sisällyttää glukoositole- 
ranssikoe, jossa glukoosin annostelu suun kautta tai injisoimalla vatsaon- 
teloon. Verinäytteenotot häntälaskimosta. Testiä edeltää paasto: hiiret noin 
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Brief Study Protocol of Toxis Ltd study 
Study number:  TOX00124-09 
Sponsor study number: - 
Study sponsor:  
Toxis Ltd Oy 
Study name:   
The hypoglycemic interaction of fosinopril and gliclazide 
in control rats and in a rat model of diabetes 
Sponsors contact person: 
- 
Test item:  
TI1  gliclazide 
TI2  fosinopril sodium 
Batch no:  
TI1 091K0060 
TI2 F4010-08-005 
Purpose of the study / problem solving:  
To study the effect of fosinopril on pharmacokinetics of gliclazide in control rats and in a rat model of 
diabetes. Plasma samples will be collected after single and repeated p.o. and i.v. administration for the 
measurement of test item concentrations in plasma. Pharmacokinetic parameters will be determined. Plasma 
glucose concentrations will be determined at baseline and approximately once a week. Oral glucose tolerance 
test (OGTT) will be performed at baseline and in the end of the study. 
Test facility:  Toxis Ltd Oy, Lemminkäisenkatu 14-18 C, 20520  Turku, FINLAND 













ca. 340 g 
 
 
ca. 310 g 
 
Age  
Ca. 14 weeks 
 




Number of groups 
6 
Vehicle 













Number of samples 
Plasma samples 720 
Study design 
 
Pharmacokinetic study on day 1 and 30: 










Sampling time points 
 on days 1 and 28 
I TI1 10 p.o. 
3 1, 5, 9 0 30 min 1 h 4 h 10 h 
3 2, 6, 10 15 min 45 min 2 h 6 h 24 h 
II TI2 10 p.o. 
3 3, 11, 15 0 30 min 1 h 4 h 10 h 







3 7, 13, 17 0 30 min 1 h 4 h 10 h 






















n # Sampling time points 
on days 1 and 28 
IV TI1 10 p.o. 
3 19, 27, 29 0 30 min 1 h 4 h 10 h 
3 20, 28, 30 15 min 45 min 2 h 6 h 24 h 
V TI2 10 p.o. 
3 23, 31, 33 0 30 min 1 h 4 h 10 h 







3 21, 25, 35 0 30 min 1 h 4 h 10 h 
3 22, 26, 36 15 min 45 min 2 h 6 h 24 h 
 
Pharmacokinetic study on day -6 and 23: 










Sampling time points 
on days -7 and 21 
I TI1 6 i.v. 
3 1, 5, 9 0 10 min 40 min 2 h 6 h 
3 2, 6, 10 5 min 20 min 1 h 4 h 10 h 
III 
TI1  6 i.v. 3 7, 13, 17 0 10 min 40 min 2 h 6 h 
TI2 10 p.o. 3 8, 14, 18 5 min 20 min 1 h 4 h 10 h 
 










Sampling time points 
on days -7 and 21 
IV TI1 6 i.v. 
3 19, 27, 29 0 10 min 40 min 2 h 6 h 
3 20, 28, 30 5 min 20 min 1 h 4 h 10 h 
VI 
TI1 6 i.v.  3 21, 25, 35 0 10 min 40 min 2 h 6 h 
TI2 10 p.o. 3 22, 26, 36 5 min 20 min 1 h 4 h 10 h 
 
 
Materials and methods 
Animal identification: Animals will be individually identified by tail numbering. Cages will be respectively 
marked with cage cards indicating study number, animal numbers, sex, strain, dose and study period. 
 
Randomisation and grouping: Animals will be grouped according to the results of the first OGT test. Diabetic 
and control rats will be put in order after the AUC of OGT test, and groups with similar average AUCs will be 
formed. No actual randomisation will be done. Animals will be grouped and numbered according to the study 
design (groups I-III rat model of diabetes and groups IV-VI control rats).  
 
Number of animals per cage: 2 
 
Bedding: Aspen chips (Tapvei Oy, Kaavi, Finland) 
 
Fodder : RM1 E SQC (SDS England), non-sterilised, ad libitum 
 
Water: Normal tap water, ad libitum 
 
A total of 18 14-week-old male Goto-Kakizaki (GK) rats and 18 10-week-old male Wistar rats weighing ca. 
310-340 g will be used. GK male rats develop a condition resembling type 2 diabetes mellitus at 













Diabetes has developed when fasted plasma glucose level exceeds 10 mmol/L (200 mg/dl).  
 
Animals will be subjected to a constant daily cycle of 12 hours of light and 12 hours darkness (06:00-18:00) 
and constant temperature (21 ± 3 ºC) and relative humidity (55 ± 15 %). Animals will be weighed once a week 
and observed for clinical signs two times a day. During weekends observations will be done once a day. 
 
Groups of control rats and rat model of diabetes will be divided in three groups each (n=6). The first subgroup 














 fosinopril orally while the third subgroup (GIII and GVI) will receive a combination of gliclazide 
and fosinopril using the same routes of administration as in the first and second subgroups.  
 




 of test items by gavage for 28 days as follows (except at study 
day 21): 
GI and IV: Gliclazide (TI1) 
GII and V: Fosinopril sodium (TI2) 
GIII and VI: Gliclazide (TI1) + Fosinopril sodium (TI2) 
 
Gliclazide will be dosed intravenously for groups I, III, IV and VI dose of 6 mg/kg on study days -6 and 23 
(see study design). 
 




Test item Gliclazide Fosinopril sodium 
Test item code TI1 TI2 
Manufacturer/ Sponsor Sigma Aldrich Euroasian Chemicals 
Batch number 091K0060 F4010-08-005 
Expiry date N/Av 03/2011 
 
 
Sampling (nature, number, size/volume, timing, etc) 
 
Blood glucose will be determined from whole blood and body weight will be measured once a week during 
experiment period.  
 
Glucose tolerance test 
After an overnight fast oral glucose tolerance test (OGTT) will be performed before daily test item dosing at 
baseline and in the end of experiment period. Rats will be given 2g/kg glucose by gavage and blood glucose 




Animals will be held in 38 
o
C for ca. 10 min before each time point for blood sampling. Total of 0,25 ml 














Study days 1 and 30: 
For pharmacokinetic evaluation, blood samples will be collected after per oral dosing at baseline and on day 
30 from lateral tail vein at time points 0, 15, 30, 45 min and 1, 2, 4, 8, 10, 24 h. The last samples will be 
collected by cardiac puncture on study day 29 (24 hrs after dosing).  
 
Study days -6 and 23: 
Blood samples will be collected on study days -6 and 23 from lateral tail vein at time points 0, 5, 10, 20, 40 
min and 1, 2, 4, 10 h  after Gliclazide (TI1) i.v. administration (see study design).  
  
The time points of dosing and blood sampling will be recorded. After sampling the blood will be centrifuged 
for plasma separation (2870 g for 10 minutes at 4 °C). After centrifugation plasma samples are transferred to 
plastic reaction tubes (Eppendorf). Plasma samples will be frozen and stored at –20 ºC. The frozen samples 
will be shipped to analysing laboratory (University of Helsinki, Faculty of Pharmacy, Department of 
Pharmaceutical Chemistry). The analysing laboratory is responsible for analysing the plasma samples. 
 
Tissue samples 
Liver, kidneys, adrenal glands and brain will be dissected immediately after cardiac puncture, snap-frozen in 
liquid nitrogen, and stored at about -80 
o
C for possible further use. The analysis of tissues is not a 
responsibility of Toxis. 
Analysis:  
Test item consentrations will be analyzed from plasma samples using LC/MS/MS- method. 
Calculations: 
The following parameters will be calculated on the basis of analyzed blood samples using a pharmacokinetic 
program Winnonlin: T1/2, AUC, Tmax, Cmax, CL, V, BA, MRT, MAT 
Time schedule: 
Preliminary dates are: 
Glucose Tolerance test                                week 21/2009  
The first dosing day (study day 0)              week 22/2009 
End of the experiment (study day 29)        weeks 27-28/2009   
Plasma analysis                                           weeks 28-31/2009 
Draft report                                                  week 36/2009 
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Some antihypertensive drugs, especially angiotensin converting enzyme (ACE) 
inhibitors, may induce hypoglycemic episodes when coadministered with hypoglycemic 
drugs, for example sulphonylureas (McMurray and Fraser 1986). This interaction 
causes several hospitalisations every year (Herings et al. 1996). The mechanism of this 
interaction is unknown. The hypothesis of this study is that the interaction is 
pharmacokinetic. Approximately 700 rat plasma samples were collected in this study 
after oral or intravenous administration of gliclazide and/or fosinopril to study the 
mechanism of the interaction.  
 
Figure 1. The chemical structures of the analytes. 
 
Gliclazide (MW=323.4 g/mol) is a hypoglycemic drug and it is classified as a 
sulphonylurea (Chiasson et al. 1991; Matthews et al. 1991) (Figure 1).  It increases the 
secretion of insulin from the pancreas and the insulin sensitivity in tissues. ACE 
inhibitor fosinoprilat (MW=435.5 g/mol) decreases blood pressure by inhibiting the 
vasoconstriction caused by the angiotensin-converting enzyme (Duchin et al. 1984; 
Duchin et al. 1985). Because the oral bioavailability of diacidic fosinoprilat is poor, a 
better absorpting phosphinic acid ester pro-drug, fosinopril (MW=563.7 g/mol), has 
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been developed. Fosinopril is rapidly hydrolyzed into fosinoprilat in gastro-intestinal 
mucosa and liver. Glibenclamide (MW=494.0 g/mol), a sulphonylurea, was used as the 
internal standad (ISTD). Deuterated derivates of the test items would serve best but 
glibenclamide is also suitable because it behaves similarly as the analytes. Foroutan et 
al. (2006) also used glibenclamide as an internal standard in a liquid 
chromatography−ultraviolet detection (LC-UV) method when analysing gliclazide. 
 
Several methods have been reported for the analysis of gliclazide, fosinopril and its 
active metabolite, fosinoprilat, in plasma/serum or pharmaceutical formulations using 
mainly LC-UV (Aburuz et al. 2005; Jancic et al. 2005) or liquid chromatography 
tandem mass spectrometry (LC-MS/MS) (Jemal et al. 2000; Wang et al. 2008). 
However, LC-UV is not sensitive and selective enough to be used in a pharmacokinetic 
study because of the complex matrix and the small concentrations of the test items in 
the samples. Jemal and Mulvana (2000) and Cui et al. (2007) studied the simultaneous 
analysis of fosinopril and fosinoprilat using LC-MS/MS. The disadvantages of the 
earlier mentioned works are for example a long (about 20 min per sample) running time 
(Aburuz et al. 2005) and multi-step SPE extractions (Jemal and Mulvana 2000, Aburuz 
et al. 2005). 
 
In order to study the pharmacokinetic interaction between gliclazide and fosinopril, a 
fast, sensitive and selective bioanalytical method was needed for the quantification of 
the test items in the large amount of plasma samples collected in this study. Since there 
already was a method for the simultaneous analysis of fosinopril and fosinoprilat in 
plasma, the work of Cui et al. (2007) was modified in this study in order to 
simultaneously also analyze gliclazide. Fosinopril could not, however, be detected 
reliably using the new method. As fosinopril is in vivo almost entirely hydrolyzed into 









2.1 Reagents and materials 
 
Gliclazide was obtained from Sigma Aldrich, Germany, fosinopril from Eurasias, India 
and fosinoprilat from Toronto Research Chemicals, Canada. The internal standard 
(ISTD), glibenclamide, was purchased from Orion, Finland. 
 
All of the reagents and other chemicals were of HPLC grade. Acetonitrile was 
purchased from Rathburn, Scotland and methanol and diethyl ether from J.T Baker, 
Holland. Dichloromethane was purchased from VWR, England and ammonium acetate 
from Riedel-deHaën, Germany. Trifluoroacetic acid (TFA) was from Sigma Aldrich, 
Germany. Water was purified with a Milli-Q water purification system (Millipore, 
France).  
 
2.2 Animal experiments 
 
Plasma samples were collected from 18 male Wistar (WI) rats (Harlan, Netherlands) 
and 18 male Goto Kakizaki (GK) rats (Taconic, Denmark) 16-17 weeks old receiving 
gliclazide and/or fosinopril orally (10 mg/kg). Animals were subjected to a constant 
daily cycle of 12 hours of light and 12 hours of darkness (06:00-18:00), constant 
temperature (21 ± 3 ºC) and relative humidity of 55 ± 15%. Two animals were housed 
in each cage. Rats had access to commercial pelleted non-sterilized chow and normal 
tap water ad libitum except during fasting when access to food was restricted. All 
procedures with animals were performed according to European Community Guidelines 
for the use of experimental animals (European Communities Council Directive 
86/609/EEC) and the experimental setup was reviewed and approved by the Animal 
Care and Use Committee of the State Provincial Office of Southern Finland.  
 
Blood samples were collected at the test site from rats’ lateral tail vein. Samples treated 
with the anticoagulant K2-EDTA were then centrifuged (2870 g for 10 minutes at 4 °C) 
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to obtain plasma. After centrifugation, plasma samples were transferred into plastic 
reaction tubes (Eppendorf) and frozen. Samples were stored at –20 ºC until analysis.  
 
Blank rat plasma (Wistar or Sprague Dawley) for standard and quality control samples 
was purchased from Toxis Ltd, Finland.   
 
2.3 Preparation of standard and quality control samples 
 
Stock solutions for the test items and the internal standard were prepared by dissolving 
accurately weighed amount of the substance into methanol and by diluting further using 
methanol. The final concentrations for the stock solutions were 0.4, 3 and 6 M for 
fosinoprilat and 1, 5 and 15 M for gliclazide. The concentration for the ISTD was 5 
M. 
 
Calibration curves were prepared approximately once a week by evaporating the 
appropriate amount of the test item and 150 l of ISTD into dryness under a gentle 
stream of nitrogen (25 
o
C) before adding 30 ul of blank plasma. Samples were made in 
triplicates and concentrations in the plasma were 5, 10, 20, 35, 45 and 60 M for 
gliclazide and 0.4, 2, 4, 8, 14, 18 and 24 M for fosinoprilat.  
 
Quality control (QC) samples were prepared as the calibration curve samples but in 
triplicates and at three concentrations representing the entire range of the standard 
curve. The concentrations were 3, 12 and 20 M for fosinoprilat and 7.5, 30 and 50 M 
for gliclazide. QC samples were prepared along with the plasma samples in each 
analytical batch and placed evenly into each run. They were used to accept each batch.  
 
2.4 Sample preparation  
 
Sample preparation was mostly done as described in the work of Cui et al. (2007). A 
total of 30 µL of defrosted plasma and 6 µL of hydrochloric acid (1.0 M) was added to 
the dry residue of 150 µL of internal standard (5 μM glibenclamide in methanol) first 
evaporated to dryness at room temperature (circa 25 
o
C) under a stream of nitrogen. The 
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samples were then briefly mixed and 200 µL of diethyl ether-dichloromethane (3:1, v/v) 
was added. Samples were extracted in a shaker for 15 minutes and then centrifuged at 
16 100 g for 15 minutes. The clear supernatant was collected and transferred into vial 
tubes were it was evaporated to dryness under a stream of nitrogen (25 
o
C). A mixture 
of methanol and aqueous 15 mM ammonium acetate solution (4:6) was then added (500 
μl) and samples were mixed to dissolve the residue.  
 
Cui et al. (2007) used a three-minute vortex-extraction to extract the analytes from 
plasma into the organic phase. Due to the large amount of samples in this study a shaker 
was used to save time. A 15-minute shaker-extraction was shown to be even more 
efficient (18% for gliclazide and 9% for fosinoprilat) than the three-minute vortex-
extraction. 
 
Some of the samples needed to be diluted with blank plasma because there was not 
enough of the plasma sample left. The results of these samples were integrated normally 





2.5.1 Liquid chromatography 
 
The experiments were performed using an Agilent HP 1100 liquid chromatograph 
(Hewlett-Packard GmbH, Germany) consisting of a binary pump, an autosampler and a 
column compartment. The column was an Atlantis
TM
 dC-18 (50 x 2.1 mm, 3 m 
particle size, Waters) and the injection wolume was 5, 10, 20 or 40 l. Methanol 
(MeOH) and 15 mM aqueous ammonium acetate were used as eluents. The linear 
gradient used for the analysis was 40-60% MeOH for 0-0.1 min, 60-90% MeOH for 
0.1-3.5 min and 90% MeOH for 3.5-5.5 min. The column was equilibrated for 1.5 
minutes before each injection. Two washing runs 90% (0.1 min) and 40% (1.5 min) 





 and the post column split ratio was 1:10. The total running time for each 
sample was 8.6 min.  
 
A column wash using 0.1% aqueous trifluoroacetic acid (TFA) and acetonitrile in three 
phases was eventually added after every batch. The first and the third phases were 
equilibration 100% of 0.1% aqueous TFA for 30 min and then wash 100% of aqueous 
TFA for 30 min. The equilibration for the second phase was 0% TFA for 30 min and the 
gradient 0-10% TFA for 0-30 min, 10-0% TFA for 30-60 min and 0-10% TFA for 60-
70 min. 
 
2.5.2 Mass spectrometry 
 
A PE Sciex API 3000 triple-quadrupole mass spectrometer (Applied Biosystems/MDS 
Sciex, Canada) with a turbo ion spray source was used for detection. Nitrogen served as 
nebulising, curtain, turbo and collision gas. The turbo gas flow rate was 6 L min
-1
 and it 
was heated to 300 
o
C. The mass spectrometer was operated in the positive ion mode 
using selected reaction monitoring (SRM). The followed reactions are shown in Table 
1. The ion spray and orifice voltages, the collision energy and the collision cell exit 
potentials for different SRM transitions were individually optimised for each 
compound. The data were collected and processed with MDS Sciex Analyst 1.5 
software. Weighting factor 1/y
2
 was used for the standard curves of fosinoprilat to place 
more emphasis on the smaller values of the curve.  
 
Table 1. Mass spectrometric parameters for the analysis of fosinoprilat, gliclazide and 
glibenclamide. The qualifier ions are shown in parenthesis. 
    CAP (V) DP FP EP CE CXP 
Gliclazide 324 → 110 (127) 5000 55 350 8 28.6 8.5 
Fosinoprilat 436 → 152 (390) 5000 63 350 8 24.9 14.0 
Glibenclamide 494 → 369  5500 50 350 8 21.0 13.2  
DP=Declustering Potential, FP=Focusing Potential, EP=Entrance Potential, CE=Collision Energy, 




2.6 Method validation 
 
The new method was validated modified according to the Food and drug administration 
(FDA) guideline for validation of bioanalytical methods (FDA 2001). Method 
validation was carried out in terms of accuracy, precision, linearity, specificity, 
reproducibility and stability. Short-term temperature stability, long-term stability, 
freeze-and-thaw stability and the stability of the stock solutions were defined. Also the 
extraction recoveries and matrix effect was studied. Accuracy and precision were 
accepted when the Relative Standard Deviation (RSD%) did not exceed 15% (20% for 
low QC) and the accuracy was within 20% of the nominal value. 
 
 
3 RESULTS AND DISCUSSION  
 
3.1 Optimization of chromatographic conditions 
 
The purpose of this study originally was to develop a method for the simultaneous 
quantification of gliclazide, fosinoprilat and fosinopril. The developed method was not, 
however, sensitive enough to detect fosinopril reliably. Since fosinopril hydrolyzes 
almost entirely into fosinoprilat, the role of fosinopril is not so significant and it was 
decided to focus on the accurate and specific detection of fosinoprilat and gliclazide 
instead.  
 
The gradient was optimized to achieve good sensitivity, efficiency and resolution and 
repeatable retention times. Different eluent compositions with different flow rates (0.3-
0.45 ml/min) were tested. The flow rate 0.45 ml/min and gradient shown in Table 2 
were chosen. The separation of fosinoprilat was complicated because it either made 
double-peak shape or the peak overlapped with fosinopril. Fosinopril was fragmented 
into fosinoprilat in the ion source and therefore they could not be separated using MS. 





Table 2. The linear gradient during the analysis and column wash. The other eluent 
component was 15 mM aqueous NH4Ac solution. 
 Time (min) MeOH (%) 
Equilibrate 1.5 40 
Run 0 40 
 0.1 60 
 3.5 90 
 5.5 90 
Wash 1 0 90 
 0.1 90 
Wash 2 0 40 
 1.5 40 
Total  8.6 min  
 
A remarkable challenge in the method development was that the retention times of the 
analytes, especially fosinoprilat, were changing and the peaks were widening during the 
run. Another issue was the strong absorption of fosinoprilat in the stainless steel 
surfaces of the hardware. This contaminated the samples analyzed later in the batch.  
 
In the study of Cui et al. (2007) they discovered that a small amount of ammonium 
acetate (10 mM aqueous solution) in the HPLC eluent improved the sensitivity, 
optimized the peak shape and also released the fosinoprilat trapped in the system. 
However, usually a big concentration of the buffer impairs the ionization of the 
analytes. In this work, ammonium acetate concentrations 5-15 mM were studied ending 
up using buffer concentration 15 mM (Figure 2). Later it was discovered that since the 
change of the buffer concentration from 10 mM to 15 mM did not solve the 
contamination problem, it would have been better to change the concentration back to 
10 mM to improve the ionization. This was not noticed at the time, however. Methanol 
containing 0.1% formic acid was also studied as the organic phase but it was less 
sensitive than pure methanol and the peak of fosinoprilat widened and the retention time 




Figure 2. The effect of the buffer concentration on the peak shape. The buffer 
concentration was first changed from 5 mM (A) to 10 mM (B) to diminish the widening 
of the peaks. C) The peak sensitivity of fosinoprilat grew worse during the time due to 
the contamination in the system. The change from 10 mM (C) to 15 mM (D) only 
decreased the sensitivity and the peak shape of fosinoprilat. The concentration of 
gliclazide (G) and fosinoprilat (F:at) is 40 µM in A and B and 45 µM (gliclazide) and 
18 µM (fosinoprilat) in C and D. ISTD is the internal standard and F is fosinopril. 
 
The adjustment of pH of the buffer was noticed to be better than the adjustment of the 
concentration of the aqueous buffer in improving the peak shape and sensitivity. Three 
different pH values were studied (pH 4.53, 4.99, 5.39). When pH 4.53 was used, the 
retention time of fosinoprilat was changing during the run (Figure 3). By adjusting the 
pH to 5.39, the retention time became repeatable. Also the separation of fosinopril and 
fosinoprilat got better. For some reason, however, the sensitivity and peak shape of 
fosinoprilat grew worse again over the time (Figure 4). The buffer pH adjustment was 





Figure 3. The effect of pH on the retention time and peak shape. In the pictures A and B 
pH is 4.53. Samples are from the beginning (A) and the end (B) of the same batch. The 
retention time of fosinoprilat is changing remarkably. In the pictures C and D pH is 
5.39. Samples are from the beginning (C) and the end (D) of the same batch. The 
retention time is repeatable but the peaks are widening during the batch. 
 
 
Figure 4. The effect of the pH on the peak shape. When the adjustment of pH was 
discontinued (B), the shape and the intensity of the fosinoprilat peak improved 
remarkably. A is before and B is after discontinuing the pH adjustment.  
 
The purpose of the sample pretreatment is to extract the analytes and to remove 
compounds that may disturb the analysis. However, some proteins might still have been 
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present in the samples after the extraction in this study and they might have attached to 
the surface of the column. This could have affected the retention of the analytes and 
could be one reason to the troubles encountered with fosinoprilat. A trifluoroacetic acid 
(TFA, 0.1%) column wash in three phases was eventually added after every batch. This 
remarkably reduced the relative contamination problem of fosinoprilat and improved 
the peak shape of fosinopilat (Figure 5).  
 
Figure 5. The effect of the column wash on the peak shape. When the column washes 
using TFA (0.1%) were added after every batch, the contamination of fosinoprilat 
diminished remarkably and sensitivity was improved. A is before and B after the 
addition of the washes. 
 
The peak area of gliclazide in some of the analyzed plasma samples was bigger than the 
peak area of the highest sample (60 M) on the standard curve. Therefore, the 
concentration of these samples was outside the given linear concentration range. 
Smaller injection volumes were used to decrease the peak area of these samples. If the 
response of the smaller injection was smaller than the highest response of the standard 
curve, it was accepted. The effect of the decreased injection volume on the peak area 
ratio of gliclazide and ISTD was studied by injecting 5, 10 and 20 ul of 50 μM QC 
sample (n=5-6). The compared injection volumes were observed to be similar and 
accurate enough (Table 3). The average concentration using injection volumes 10 µl 

















20 50 50.4 2.2 100.8 
10 50 52.4 2.8 104.8 
5 50 52.3 2.2 104.5 
 
3.2 Selection of LC-MS/MS conditions 
 
Negative and positive ionisation mode was tested and positive ionisation mode was 
selected for the method because the sensitivity was better. Selected reaction monitoring 
(SRM) was used and the reactions giving the most intensive signals, m/z 324 → 110 and 
m/z 324 → 127 for gliclazide, m/z 436 → 152 and m/z 436 → 390 for fosinoprilat and 
m/z 494 → 369 for the internal standard, were monitored. All the MS parameters were 




 ions of analytes are 
shown in Table 4. The main product ion in the positive ionisation mode mass spectrum 
was [M+H]
+
 for all the analytes. Fragmentation was moderate which indicates a good 
stability of the protonated molecules in the electrospray ionisation. Some proposed 
structures of the fragments seen in the positive ion mode mass spectrum of gliclazide 

















Table 4. The main peaks found in the positive and negative ionisation mode MS and 
MS/MS spectra of gliclazide, fosinoprilat and ISTD. Collision energy was ramped 
between 5 and 70 V in MS/MS analysis. 









   
Gliclazide 324.4 346.4 362.4 - 127.1, 153.1 
Fosinoprilat 436.4 458.5 474.5 - 390.4, 418.4 
ISTD 494.3 - 533.0 512.0 369.2, 395.3 
            
  m/z in the product ion spectrum of [M+H]+    
Gliclazide 81.1, 91.3, 110.2, 111.2, 127.2, 153.2, 155.2, 168.2, 324.2 
Fosinoprilat 109.2, 152.3, 198.1, 390.3, 418.2, 436.2   
ISTD 100.3, 169.1, 198.0, 259.3, 288.2, 304.2, 369.1, 395.1, 494.2 
      
Compound m/z in the MS spectrum, negative ion mode Fragments 
  [M-H]
- 
         
Gliclazide 322.5       - 
Fosinoprilat 434.4       - 
ISTD 492.2       367.2 
            
  m/z in the product ion spectrum of [M-H]
-
    
Gliclazide 62.0, 79.9, 104.1, 106.1, 170.0, 322.1   
Fosinoprilat 62.9, 195.0, 213.1, 237.1, 390.3, 434.4   




Figure 6. Proposed mass fragmentation patterns of gliclazide (modified Bansal et al. 
2008). 
 
3.3 Method validation 
 
The method was successfully validated modified according to the FDA guideline for 
validation of bioanalytical methods (FDA 2001). The accuracy, precision, linearity, 
specificity, stability and reproducibility of the method were determined. The extraction 
recovery and matrix effect were also studied. 
 
During routine analysis, each analytical batch included two blank samples, a set of QC 
samples and the plasma samples. The blank samples were prepared as the standard 
samples by adding pure methanol instead of the analytes. Residues were dissolved 
either in water or plasma. Three concentrations (3.3, 12 and 20 µM for fosinoprilat and 
8.3, 30 and 50 µM for gliclazide) in triplicates representing the entire range of the 
standard curve were analyzed as Quality Control (QC) samples in each batch (Table 5). 
The acceptance criteria for the QC samples were RSD  15% (20% for low QC) and 
accuracy  20% of the nominal value. Qualification ions were also used when 
quantification ions did not full the criteria. The developed method was not sensitive 
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enough to detect fosinopril reliably and therefore only the validation results for 
fosinoprilat and gliclazide will be reported. 
 












 8.3 8.6 2.3 5.5 103.9 
Gliclazide 30 31.3 5.3 4.2 104.3 
 50 50.5 5.3 3.9 100.9 
      
 3.3 3.3 2.6 6.1 99.9 
Fosinoprilat 12 11.9 1.8 8.1 99.3 
 20 20.9 2.7 3.8 104.3 
 
A standard curve, covering the entire range of expected concentrations in plasma 
samples, was prepared in triplicates approximately once a week (Table 6). The slope, 
the intercept and the correlation coefficient were determined from every curve. The 
mean y intercepts were 0.6057 for gliclazide and -0.2146 for fosinoprilat. The mean 
slopes were 0.9856 for gliclazide and 1.0433 for fosinoprilat. On the basis of acceptable 
accuracy and good correlation coefficients (≥0.9905), the relationship between area 
ratio and concentrations was linear within the studied concentration range. Values for 














Table 6. The precision, accuracy and linearity of the standard curves (n=10-11) 
Gliclazide       
Concentration (μM) Mean (μM) RSD (%) Accuracy (%) 
5 4.91 8.9 98.2 
10 10.75 4.9 107.5 
20 21.52 4.5 107.6 
35 35.17 4.5 100.5 
45 44.90 3.0 99.8 
60 59.36 2.4 98.9 
    
r
2
 0.9905 - 0.9990   
    
Fosinoprilat       
Concentration (μM) Mean (μM) RSD (%) Accuracy (%) 
0.4 0.41 0.9 101.4 
2 2.01 5.2 100.7 
4 3.87 4.9 96.8 
8 7.97 2.5 99.7 
14 14.14 3.5 101.0 
18 18.37 4.0 102.1 
24 25.17 3.9 104.9 
    
r
2
 0.9934 - 0.9999   
 
In order to show precision and accuracy, within-day and between-days variations were 
determined (Table 5). Quality Control samples at three concentrations with 5 injections 
for each concentration were used. Within-day precision ranged from 1.8% to 5.3% and 
between-days precision from 3.8% to 8.1%. The mean accuracy ranged from 99.3% to 




Figure 7. Positive ion SRM chromatograms of the analytes. A) A known concentration 
of the analytes in plasma (G 30 µM, F 4 µM and ISTD 5 µM), B) an unknown amount 
of analytes in plasma samples and C) blank plasma samples. 
 
The SRM chromatograms of the analytes from blank, standard and plasma samples are 
shown in Figure 7. The specificity of the method was good for gliclazide. There is no 
other substances present having the same retention time. However, Figure 7 shows 
significant peaks for fosinoprilat and ISTD in the blank samples. This is due to the 
contamination in the system. The contamination for ISTD is moderate (signal-to-noise 
ratio, S/N = 11.2) and even higher for fosinoprilat (S/N = 21). S/N for ISTD in the 
spiked samples was, however, thousands of times higher than in the blank samples. The 
limit of detection (LOD, S/N of at least 3) and the limit of quantification (LOQ, S/N of 
at least 10) were determined for all the analytes. In the cases where contamination was 
observed in the blank sample, LODs and LOQs were determined with a concentration 
that produced a S/N ratio three or ten times higher than the peak of the blank sample. 
The LOQ for gliclazide was 1 μM. The LOD for fosinoprilat varied from 0.4 μM to 4 





Figure 8. The recovery and the matrix effect of the analytes as analyte peak area (n=2-6, 
mean ±SD). 
 
The recovery (extraction efficiency) of the analytes from rat plasma and the matrix 
effect were determined at one concentration (40 M). To study recovery the ISTD 
corrected peak areas of analytes added in plasma before extraction were compared with 
those where analytes were added in plasma after extraction (Figure 8). Calculated 
concentrations of the same samples are shown and compared in Figure 9. The recovery 
was 79.1% for fosinoprilat and 122.4% for gliclazide. The recovery of the extracted 
samples was tolerable. Matrix effect was calculated by comparing the concentration of 
the analytes added in plasma after extraction with the concentration of analytes added in 
eluent (100% recovery). It was discovered that the plasma matrix caused ion 























Figure 9. The recovery and the matrix effect of the analytes as concentration (n=2-6, 
mean ±SD). 
 
The stability of analytes was studied by determining the concentration of six 50 μM QC 
samples before and after a 24-hour storage in -20 
o
C (Figure 10). In addition to this 
three 50+20 μM QC samples were exposed to different time and temperature 
conditions: a) stability at room temperature for 24 h, b) stability after two freeze–thaw 
cycles and c) the long-term stability after storage at -20 ° C for 4 days (Table 7). These 
samples were not analyzed before storing, only after. Results showed good stability for 
all analytes in different circumstances. The stability of the stock solutions was studied 
in -20 
o






























Figure 10. The concentration of analytes (QC 50 μM) before and after a 24-hour storage 
in -20 
o
C (n=6, mean ±SD). 
 
Table 7. The stability of the analytes in rat plasma in different conditions (QC sample 
50+20 μM, n=3). 
  - 20 °C / 4 days - 20 °C / 2 freeze-thaw Room  
    cycles temperature / 12 h 
Gliclazide (μM) 49.1 55.1 57.8 
RSD (%) 2.8 9.3 4.1 
    
Fosinoprilat (μM) 21.8 19.7 19.4 





In this study a LC-MS/MS method was developed and validated for the simultaneous 
analysis of fosinoprilat and gliclazide. The determination of fosinopril failed due to 
sensitivity problems. The new method is based on a modified version of the work of Cui 
et al. (2007).  
 
Accuracy, precision, linearity, specificity, stability and reproducibility of the method 
were shown to be good. The extraction recovery and matrix effect also complied with 
the requirements. There were some contamination problems in the analytical system for 




























every analytical batch. This method was successfully used to analyze approximately 
700 plasma samples collected from rats receiving gliclazide and/or fosinopril (10 
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 APPENDIX 4 
 
Raw data of the pharmacokinetic studies. The column ”concentration” represents the 
concentration of gliclazide in the plasma samples in the beginning and at the end of the 

















1,2 0   0  0,301 
1,2 0,08   0,25 3,107 3,768 
1,2 0,17 61,700 39,781 0,5 4,496 10,527 
1,2 0,33  38,810 0,75 7,681 7,148 
1,2 0,67 22,106 31,267 1 9,331 15,314 
1,2 1 22,251 23,319 2 13,276 17,546 
1,2 2 12,201 19,446 4 21,879 11,870 
1,2 4 13,099 13,770 6 15,055 18,014 
1,2 6 3,539 6,873 10 9,298 5,595 
1,2 10 3,946 2,628 24  1,087 
1,6 0   0  0,301 
1,6 0,08   0,25 0,846 2,992 
1,6 0,17 61,700 39,781 0,5 4,496 10,527 
1,6 0,33  27,183 0,75 2,450 7,924 
1,6 0,67 22,106 31,267 1 9,331 15,314 
1,6 1  17,934 2 5,708 16,527 
1,6 2 12,201 19,446 4 21,879 11,870 
1,6 4  11,166 6 12,508 17,004 
1,6 6 3,539 6,873 10 9,298 5,595 
1,6 10  2,628 24   
1,10 0   0  0,301 
1,10 0,08 37,112 42,287 0,25 0,594 4,099 
1,10 0,17 61,700 39,781 0,5 4,496 10,527 
1,10 0,33 31,566 37,274 0,75 2,406 8,191 
1,10 0,67 22,106 31,267 1 9,331 15,314 
1,10 1 28,404 29,714 2 6,113 14,942 
1,10 2 12,201 19,446 4 21,879 11,870 
1,10 4 14,158 14,239 6 10,406 16,179 
1,10 6 3,539 6,873 10 9,298 5,595 
1,10 10 2,516 3,170 24  0,234 
5,2 0   0   
5,2 0,08   0,25 3,107 3,768 
5,2 0,17 20,214  0,5 3,687  
5,2 0,33  38,810 0,75 7,681 7,148 
  
5,2 0,67 18,944  1 7,568  
5,2 1 22,251 23,319 2 13,276 17,546 
5,2 2 13,228  4 14,974  
5,2 4 13,099 13,770 6 15,055 18,014 
5,2 6 4,124  10 8,716  
5,2 10 3,946 2,628 24  1,087 
5,6 0   0   
5,6 0,08   0,25 0,846 2,992 
5,6 0,17 20,214  0,5 3,687  
5,6 0,33  27,183 0,75 2,450 7,924 
5,6 0,67 18,944  1 7,568  
5,6 1  17,934 2 5,708 16,527 
5,6 2 13,228  4 14,974  
5,6 4  11,166 6 12,508 17,004 
5,6 6 4,124  10 8,716  
5,6 10  2,628 24   
5,10 0   0   
5,10 0,08 37,112 42,287 0,25 0,594 4,099 
5,10 0,17 20,214  0,5 3,687  
5,10 0,33 31,566 37,274 0,75 2,406 8,191 
5,10 0,67 18,944  1 7,568  
5,10 1 28,404 29,714 2 6,113 14,942 
5,10 2 13,228  4 14,974  
5,10 4 14,158 14,239 6 10,406 16,179 
5,10 6 4,124  10 8,716  
5,10 10 2,516 3,170 24  0,234 
9,2 0   0  0,374 
9,2 0,08   0,25 3,107 3,768 
9,2 0,17 33,215 30,434 0,5 3,784 8,449 
9,2 0,33  38,810 0,75 7,681 7,148 
9,2 0,67 25,558 27,305 1 6,210 15,767 
9,2 1 22,251 23,319 2 13,276 17,546 
9,2 2 19,583 21,378 4 11,756 21,855 
9,2 4 13,099 13,770 6 15,055 18,014 
9,2 6 9,371 9,274 10 5,886 18,589 
9,2 10 3,946 2,628 24  1,087 
9,6 0   0  0,374 
9,6 0,08   0,25 0,846 2,992 
9,6 0,17 33,215 30,434 0,5 3,784 8,449 
9,6 0,33  27,183 0,75 2,450 7,924 
9,6 0,67 25,558 27,305 1 6,210 15,767 
9,6 1  17,934 2 5,708 16,527 
9,6 2 19,583 21,378 4 11,756 21,855 
9,6 4  11,166 6 12,508 17,004 
  
9,6 6 9,371 9,274 10 5,886 18,589 
9,6 10  2,628 24   
9,10 0   0  0,374 
9,10 0,08 37,112 42,287 0,25 0,594 4,099 
9,10 0,17 33,215 30,434 0,5 3,784 8,449 
9,10 0,33 31,566 37,274 0,75 2,406 8,191 
9,10 0,67 25,558 27,305 1 6,210 15,767 
9,10 1 28,404 29,714 2 6,113 14,942 
9,10 2 19,583 21,378 4 11,756 21,855 
9,10 4 14,158 14,239 6 10,406 16,179 
9,10 6 9,371 9,274 10 5,886 18,589 
9,10 10 2,516 3,170 24  0,234 
7,8 0   0  0,513 
7,8 0,08  33,401 0,25 5,336 3,112 
7,8 0,17 14,699 36,870 0,5 3,687 4,808 
7,8 0,33  29,876 0,75 10,519 8,304 
7,8 0,67 14,206 33,555 1 7,422 10,034 
7,8 1  18,637 2 18,669 18,128 
7,8 2 9,460 25,728 4 13,721 17,748 
7,8 4  10,042 6 13,899 21,200 
7,8 6  9,864 10 6,501 9,533 
7,8 10  3,105 24   
7,14 0   0  0,513 
7,14 0,08  50,939 0,25   
7,14 0,17 14,699 36,870 0,5 3,687 4,808 
7,14 0,33  38,244 0,75   
7,14 0,67 14,206 33,555 1 7,422 10,034 
7,14 1  37,759 2 13,082 16,397 
7,14 2 9,460 25,728 4 13,721 17,748 
7,14 4   6 17,378 21,055 
7,14 6  9,864 10 6,501 9,533 
7,14 10   24 0,121 0,780 
7,18 0   0  0,513 
7,18 0,08 27,103  0,25   
7,18 0,17 14,699 36,870 0,5 3,687 4,808 
7,18 0,33 21,936  0,75   
7,18 0,67 14,206 33,555 1 7,422 10,034 
7,18 1 10,552  2   
7,18 2 9,460 25,728 4 13,721 17,748 
7,18 4   6   
7,18 6  9,864 10 6,501 9,533 
7,18 10   24   
13,8 0   0  1,210 
13,8 0,08  33,401 0,25 5,336 3,112 
  
13,8 0,17  41,851 0,5 4,364 7,253 
13,8 0,33  29,876 0,75 10,519 8,304 
13,8 0,67  33,878 1 10,358 9,080 
13,8 1  18,637 2 18,669 18,128 
13,8 2  25,130 4  15,120 
13,8 4  10,042 6 13,899 21,200 
13,8 6  11,829 10 10,180 9,064 
13,8 10  3,105 24   
13,14 0   0  1,210 
13,14 0,08  50,939 0,25   
13,14 0,17  41,851 0,5 4,364 7,253 
13,14 0,33  38,244 0,75   
13,14 0,67  33,878 1 10,358 9,080 
13,14 1  37,759 2 13,082 16,397 
13,14 2  25,130 4  15,120 
13,14 4   6 17,378 21,055 
13,14 6  11,829 10 10,180 9,064 
13,14 10   24 0,121 0,780 
13,18 0   0  1,210 
13,18 0,08 27,103  0,25   
13,18 0,17  41,851 0,5 4,364 7,253 
13,18 0,33 21,936  0,75   
13,18 0,67  33,878 1 10,358 9,080 
13,18 1 10,552  2   
13,18 2  25,130 4  15,120 
13,18 4   6   
13,18 6  11,829 10 10,180 9,064 
13,18 10   24   
17,8 0   0   
17,8 0,08  33,401 0,25 5,336 3,112 
17,8 0,17 31,598 33,223 0,5  4,059 
17,8 0,33  29,876 0,75 10,519 8,304 
17,8 0,67 27,232 28,307 1 0,886 8,199 
17,8 1  18,637 2 18,669 18,128 
17,8 2 19,491 22,025 4 8,037 13,244 
17,8 4  10,042 6 13,899 21,200 
17,8 6 6,177 7,107 10 4,075 7,342 
17,8 10  3,105 24   
17,14 0   0   
17,14 0,08  50,939 0,25   
17,14 0,17 31,598 33,223 0,5  4,059 
17,14 0,33  38,244 0,75   
17,14 0,67 27,232 28,307 1 0,886 8,199 
17,14 1  37,759 2 13,082 16,397 
  
17,14 2 19,491 22,025 4 8,037 13,244 
17,14 4   6 17,378 21,055 
17,14 6 6,177 7,107 10 4,075 7,342 
17,14 10   24 0,121 0,780 
17,18 0   0   
17,18 0,08 27,103  0,25   
17,18 0,17 31,598 33,223 0,5  4,059 
17,18 0,33 21,936  0,75   
17,18 0,67 27,232 28,307 1 0,886 8,199 
17,18 1 10,552  2   
17,18 2 19,491 22,025 4 8,037 13,244 
17,18 4   6   
17,18 6 6,177 7,107 10 4,075 7,342 
17,18 10   24   
19,20 0   0   
19,20 0,08 31,889 46,977 0,25 4,593 3,541 
19,20 0,17  56,599 0,5 4,900 9,339 
19,20 0,33 16,373 20,853 0,75 12,064 12,411 
19,20 0,67  41,802 1 10,244 21,111 
19,20 1 14,627 14,093 2 20,133 22,300 
19,20 2  21,847 4 21,516 19,171 
19,20 4 3,954 3,315 6 12,775 9,840 
19,20 6  5,587 10 6,072 6,606 
19,20 10 0,275  24   
19,28 0   0   
19,28 0,08 49,079 32,415 0,25 1,194 4,439 
19,28 0,17  56,599 0,5 4,900 9,339 
19,28 0,33 15,605 23,496 0,75 4,107 14,513 
19,28 0,67  41,802 1 10,244 21,111 
19,28 1 11,926 18,063 2 14,053 18,985 
19,28 2  21,847 4 21,516 19,171 
19,28 4 3,243 4,924 6 8,821 10,859 
19,28 6  5,587 10 6,072 6,606 
19,28 10 5,328 0,166 24   
19,30 0   0   
19,30 0,08  84,089 0,25 3,647 2,942 
19,30 0,17  56,599 0,5 4,900 9,339 
19,30 0,33 34,929 52,071 0,75 10,296 10,888 
19,30 0,67  41,802 1 10,244 21,111 
19,30 1 18,006 38,487 2 16,009 16,246 
19,30 2  21,847 4 21,516 19,171 
19,30 4 6,361 12,085 6 7,557 19,297 
19,30 6  5,587 10 6,072 6,606 
19,30 10 0,593 1,618 24 0,997  
  
27,20 0   0   
27,20 0,08 31,889 46,977 0,25 4,593 3,541 
27,20 0,17 33,393 31,331 0,5 5,676 6,719 
27,20 0,33 16,373 20,853 0,75 12,064 12,411 
27,20 0,67 19,397 26,957 1 10,867 10,180 
27,20 1 14,627 14,093 2 20,133 22,300 
27,20 2 12,403 16,220 4 14,643 12,710 
27,20 4 3,954 3,315 6 12,775 9,840 
27,20 6 3,355 3,824 10 2,992 6,509 
27,20 10 0,275  24   
27,28 0   0   
27,28 0,08 49,079 32,415 0,25 1,194 4,439 
27,28 0,17 33,393 31,331 0,5 5,676 6,719 
27,28 0,33 15,605 23,496 0,75 4,107 14,513 
27,28 0,67 19,397 26,957 1 10,867 10,180 
27,28 1 11,926 18,063 2 14,053 18,985 
27,28 2 12,403 16,220 4 14,643 12,710 
27,28 4 3,243 4,924 6 8,821 10,859 
27,28 6 3,355 3,824 10 2,992 6,509 
27,28 10 5,328 0,166 24   
27,30 0   0   
27,30 0,08  84,089 0,25 3,647 2,942 
27,30 0,17 33,393 31,331 0,5 5,676 6,719 
27,30 0,33 34,929 52,071 0,75 10,296 10,888 
27,30 0,67 19,397 26,957 1 10,867 10,180 
27,30 1 18,006 38,487 2 16,009 16,246 
27,30 2 12,403 16,220 4 14,643 12,710 
27,30 4 6,361 12,085 6 7,557 19,297 
27,30 6 3,355 3,824 10 2,992 6,509 
27,30 10 0,593 1,618 24 0,997  
29,20 0   0   
29,20 0,08 31,889 46,977 0,25 4,593 3,541 
29,20 0,17  26,149 0,5 5,150 6,441 
29,20 0,33 16,373 20,853 0,75 12,064 12,411 
29,20 0,67 16,632 22,300 1 11,077 9,145 
29,20 1 14,627 14,093 2 20,133 22,300 
29,20 2 12,088 17,311 4 9,120 18,346 
29,20 4 3,954 3,315 6 12,775 9,840 
29,20 6 4,819 7,115 10 5,062 8,385 
29,20 10 0,275  24   
29,28 0   0   
29,28 0,08 49,079 32,415 0,25 1,194 4,439 
29,28 0,17  26,149 0,5 5,150 6,441 
29,28 0,33 15,605 23,496 0,75 4,107 14,513 
  
29,28 0,67 16,632 22,300 1 11,077 9,145 
29,28 1 11,926 18,063 2 14,053 18,985 
29,28 2 12,088 17,311 4 9,120 18,346 
29,28 4 3,243 4,924 6 8,821 10,859 
29,28 6 4,819 7,115 10 5,062 8,385 
29,28 10 5,328 0,166 24   
29,30 0   0   
29,30 0,08  84,089 0,25 3,647 2,942 
29,30 0,17  26,149 0,5 5,150 6,441 
29,30 0,33 34,929 52,071 0,75 10,296 10,888 
29,30 0,67 16,632 22,300 1 11,077 9,145 
29,30 1 18,006 38,487 2 16,009 16,246 
29,30 2 12,088 17,311 4 9,120 18,346 
29,30 4 6,361 12,085 6 7,557 19,297 
29,30 6 4,819 7,115 10 5,062 8,385 
29,30 10 0,593 1,618 24 0,997  
21,22 0   0   
21,22 0,08 70,263 45,360 0,25 2,495 3,128 
21,22 0,17  44,147 0,5 9,004 11,740 
21,22 0,33 18,079 40,832 0,75 7,835 8,094 
21,22 0,67  30,159 1 16,915 19,190 
21,22 1 17,117 21,378 2 19,033 23,238 
21,22 2  19,648 4 16,131 13,171 
21,22 4 5,320 5,854 6 7,471 8,538 
21,22 6  5,256 10 3,930 4,601 
21,22 10 0,338 0,365 24   
21,26 0   0   
21,26 0,08  44,228 0,25 1,112 1,797 
21,26 0,17  44,147 0,5 9,004 11,740 
21,26 0,33  28,712 0,75 6,210 11,498 
21,26 0,67  30,159 1 16,915 19,190 
21,26 1  19,567 2 15,718 19,615 
21,26 2  19,648 4 16,131 13,171 
21,26 4  5,943 6 10,333 6,824 
21,26 6  5,256 10 3,930 4,601 
21,26 10   24   
21,36 0   0   
21,36 0,08 35,738  0,25 4,447  
21,36 0,17  44,147 0,5 9,004 11,740 
21,36 0,33 29,051  0,75 12,807  
21,36 0,67  30,159 1 16,915 19,190 
21,36 1 23,965  2 19,122  
21,36 2  19,648 4 16,131 13,171 
21,36 4 10,192  6 14,376  
  
21,36 6  5,256 10 3,930 4,601 
21,36 10 1,685  24   
25,22 0   0   
25,22 0,08 70,263 45,360 0,25 2,495 3,128 
25,22 0,17 33,878 41,074 0,5 5,498 6,468 
25,22 0,33 18,079 40,832 0,75 7,835 8,094 
25,22 0,67 27,127 34,384 1 9,573 12,888 
25,22 1 17,117 21,378 2 19,033 23,238 
25,22 2 18,920 18,969 4 5,142 17,246 
25,22 4 5,320 5,854 6 7,471 8,538 
25,22 6 4,229 4,371 10 2,090 3,194 
25,22 10 0,338 0,365 24   
25,26 0   0   
25,26 0,08  44,228 0,25 1,112 1,797 
25,26 0,17 33,878 41,074 0,5 5,498 6,468 
25,26 0,33  28,712 0,75 6,210 11,498 
25,26 0,67 27,127 34,384 1 9,573 12,888 
25,26 1  19,567 2 15,718 19,615 
25,26 2 18,920 18,969 4 5,142 17,246 
25,26 4  5,943 6 10,333 6,824 
25,26 6 4,229 4,371 10 2,090 3,194 
25,26 10   24   
25,36 0   0   
25,36 0,08 35,738  0,25 4,447  
25,36 0,17 33,878 41,074 0,5 5,498 6,468 
25,36 0,33 29,051  0,75 12,807  
25,36 0,67 27,127 34,384 1 9,573 12,888 
25,36 1 23,965  2 19,122  
25,36 2 18,920 18,969 4 5,142 17,246 
25,36 4 10,192  6 14,376  
25,36 6 4,229 4,371 10 2,090 3,194 
25,36 10 1,685  24   
35,22 0   0   
35,22 0,08 70,263 45,360 0,25 2,495 3,128 
35,22 0,17 29,933 29,367 0,5 6,210 6,420 
35,22 0,33 18,079 40,832 0,75 7,835 8,094 
35,22 0,67 21,184 23,108 1 11,118 8,724 
35,22 1 17,117 21,378 2 19,033 23,238 
35,22 2 14,004 14,691 4 11,255 10,042 
35,22 4 5,320 5,854 6 7,471 8,538 
35,22 6 2,876 3,580 10 2,194 5,991 
35,22 10 0,338 0,365 24   
35,26 0   0   
35,26 0,08  44,228 0,25 1,112 1,797 
  
35,26 0,17 29,933 29,367 0,5 6,210 6,420 
35,26 0,33  28,712 0,75 6,210 11,498 
35,26 0,67 21,184 23,108 1 11,118 8,724 
35,26 1  19,567 2 15,718 19,615 
35,26 2 14,004 14,691 4 11,255 10,042 
35,26 4  5,943 6 10,333 6,824 
35,26 6 2,876 3,580 10 2,194 5,991 
35,26 10   24   
35,36 0   0   
35,36 0,08 35,738  0,25 4,447  
35,36 0,17 29,933 29,367 0,5 6,210 6,420 
35,36 0,33 29,051  0,75 12,807  
35,36 0,67 21,184 23,108 1 11,118 8,724 
35,36 1 23,965  2 19,122  
35,36 2 14,004 14,691 4 11,255 10,042 
35,36 4 10,192  6 14,376  
35,36 6 2,876 3,580 10 2,194 5,991 
35,36 10 1,685  24   
 

























1,10 0 1,83 3,04  1,10 0 2,05 3,42 
1,2 0 1,83 3,04  1,2 0 2,05 3,42 
1,6 0 1,83 3,04  1,6 0 2,05 3,42 
5,10 0 1,83 3,04  5,10 0 2,05 3,42 
5,2 0 1,83 3,04  5,2 0 2,05 3,42 
5,6 0 1,83 3,04  5,6 0 2,05 3,42 
9,10 0 1,83 3,04  9,10 0 2,05 3,42 
9,2 0 1,83 3,04  9,2 0 2,05 3,42 
9,6 0 1,83 3,04  9,6 0 2,05 3,42 
7,14 0 1,87 3,11  7,14 0 2,07 3,45 
7,18 0 1,87 3,11  7,18 0 2,07 3,45 
7,8 0 1,87 3,11  7,8 0 2,07 3,45 
13,14 0 1,87 3,11  13,14 0 2,07 3,45 
13,18 0 1,87 3,11  13,18 0 2,07 3,45 
13,8 0 1,87 3,11  13,8 0 2,07 3,45 
17,14 0 1,87 3,11  17,14 0 2,07 3,45 
17,18 0 1,87 3,11  17,18 0 2,07 3,45 
17,8 0 1,87 3,11  17,8 0 2,07 3,45 
19,20 0 2,00 3,34  19,20 0 2,55 4,26 
19,28 0 2,00 3,34  19,28 0 2,55 4,26 
19,30 0 2,00 3,34  19,30 0 2,55 4,26 
  
27,20 0 2,00 3,34  27,20 0 2,55 4,26 
27,28 0 2,00 3,34  27,28 0 2,55 4,26 
27,30 0 2,00 3,34  27,30 0 2,55 4,26 
29,20 0 2,00 3,34  29,20 0 2,55 4,26 
29,28 0 2,00 3,34  29,28 0 2,55 4,26 
29,30 0 2,00 3,34  29,30 0 2,55 4,26 
21,22 0 2,01 3,34  21,22 0 2,47 4,12 
21,26 0 2,01 3,34  21,26 0 2,47 4,12 
21,36 0 2,01 3,34  21,36 0 2,47 4,12 
25,22 0 2,01 3,34  25,22 0 2,47 4,12 
25,26 0 2,01 3,34  25,26 0 2,47 4,12 
25,36 0 2,01 3,34  25,36 0 2,47 4,12 
35,22 0 2,01 3,34  35,22 0 2,47 4,12 
35,26 0 2,01 3,34  35,26 0 2,47 4,12 
35,36 0 2,01 3,34  35,36 0 2,47 4,12 
 
